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ABSTRACT 
Cardiac diseases are common in dogs and are associated with ventricular 
dilatation or hypertrophy as well as cardiac dysfunction. In cardiac diseases, 
activation of the neurohormonal and inflammatory systems contribute to cardiac 
remodelling through degradation or increased deposition (fibrosis) of the extracellular 
matrix (ECM). Important factors in this process are cytokines as mediators of 
inflammation, matrix metalloproteinases (MMP) and their inhibitors (tissue inhibitors 
of metalloproteinases; TIMP) as regulators of the myocardial ECM composition. 
Recently, there was evidence that also leptin plays a role in human cardiac diseases. 
However, the precise mechanisms that cause pathological cardiac remodelling in 
both humans and other mammalian species are incompletely understood. 
Furthermore, functional impairment of the heart and cardiomyocyte damage are 
observed in human and canine patients with systemic diseases, again without 
current knowledge on the underlying process.  
The aim of the present studies was to investigate cardiac remodelling in canine 
patients with cardiac and systemic diseases. For this purpose, a quantitative 
assessment of the transcription of cytokines (IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, 
IFN-γ, TGF-β1, TGF-β2, TGF-β3), MMP (MMP-1, -2, -3, -9, -13), TIMP (TIMP-1, -2, -
3, -4) and leptin in the blood of healthy dogs and dogs with cardiac diseases and in 
the myocardium of dogs with cardiac diseases, dogs with systemic diseases not 
involving the heart as well as healthy control dogs was obtained.  
In comparison to healthy dogs, which constitutively transcribed most markers in 
blood, dogs with cardiac diseases exhibited a selective increase (IL-1, IL-2, MMP-1, -
3, TIMP-3) or reduction (TNF-α, TGF-β1, -β3, TIMP-1, -2) of inflammatory and ECM 
remodelling markers and an increase of leptin. In contrast, in the myocardium of 
dogs with cardiac and systemic diseases, the transcription of all markers was 
significantly higher than in hearts of healthy control dogs. This suggests myocardial 
inflammation and remodelling not only in association with cardiac diseases, but also 
with systemic diseases that do not involve the heart. The results also indicate a 
localised myocardial inflammation and remodelling in dogs with cardiac diseases, not 
secondary to a systemic inflammatory response. Interestingly, transcription levels of 
most markers exhibited regional differences in diseased dogs in general, with 
 
 
significantly higher mRNA levels in atria than in ventricles. This indicates differences 
in the remodelling processes depending on localisation, which was reflected by more 
severe histological changes in the atria of dogs with cardiac diseases.  
In conclusion, the results of the thesis provide evidence of myocardial 
inflammation and remodelling with regional quantitative differences in dogs with 
cardiac and systemic diseases and suggest a role for leptin in canine cardiac 
disease. The results provide further insights into the complex process of cardiac 
remodelling, which might influence clinical management and the assessment of 
prognoses in future. 
 
 
ACKNOWLEDGEMENTS 
The present thesis was carried out at the Section of Veterinary Pathology and 
Parasitology, Department of Veterinary Bioscience, Faculty of Veterinary Medicine at 
the University of Helsinki and the School of Veterinary Science, University of 
Liverpool. Financial support was kindly provided by a grant from the University of 
Liverpool for consumables and personal grants from the Aarne ja Aili Turunen säätiö, 
Finland and the Helvi Knuuttilan Fund.  
This work would not have been possible without the support from many people. In 
particular, I would like to express my sincere gratitude to: 
Prof Anja Kipar, my main supervisor, for professionally and genuinely supporting 
my scientific work, for introducing me to the pathologists’ approach to cardiology, 
and for the valuable and thoroughly performed review of the manuscript. Your 
enormous scientific expertise has been invaluable for me. Thank you for always 
being available and quickly replying to any question that may arise. I do appreciate 
all scientific discussions we had, your advice on all aspects of life and your 
friendship. Thank you for accommodation and taking care of me wherever we are.  
Dr Maria Wiberg, my co-supervisor, for professionally supporting my scientific 
work and the valuable manuscript feedback.  
Dr Dr Udo Hetzel, my co-supervisor, for sharing your knowledge of cardiac and 
other aspects of pathology, and my interest in hearts and for always being open to 
new ideas. Thank you for uncountable long evenings with discussions about life and 
red wine, I hope there will be many to follow. 
Prof Antti Sukura, Dean of the Faculty of Veterinary Medicine, for placing the 
facilities of the Section of Veterinary Pathology and Parasitology at my disposal. 
Dr Joanna Dukes McEwan, my supervisor during my residency at the University 
of Liverpool, for disclosing the exciting world of cardiology, for your energy to teach 
me, for all your support scientifically and professionally, and for sharing my 
enthusiasm about the pathology aspect of cardiology. Thank you for always quickly 
and critically reviewing manuscripts. 
Prof Peter Clegg and Dr Simon Tew at the University of Liverpool, for supporting 
my scientific work and for placing the laboratories and consumables in Leahurst at 
 
 
my disposal. I appreciate your support and your availability and expertise in 
discussing technical problems. Dr Peter Cripps at the University of Liverpool, for 
helping with the statistical analysis of the data. Thank you for being so patient with 
me! 
Kati Holmsten and Krista Weber at the University of Helsinki, for introducing me 
to the laboratories in Helsinki, and for helping with any technical problems that may 
arise.  
The former cardiology team in Liverpool, Simon Swift and Joao Loureiro, for 
supporting my first steps and exploring the world of cardiology with me, for countless 
interesting discussions about cardiology and other parts of life, for being great 
teachers and friends, and for creating a great working atmosphere, which made also 
stressful days enjoyable. I am privileged having worked with you and having you as 
friends. Jordi Lopez Alvarez for having been a great office mate and travel 
companion and for your friendship. Thanks for all your advice about life. Hannah 
Stephenson for being a great colleague. All colleagues and staff in Liverpool for 
making my time in Liverpool an amazing experience and for remembering my 
interest in heart samples, David Killick for organizing the control samples, Julien 
Dandrieux for cheering up my days with coffee and food, Mary Marrington and 
Aran Mas for their friendship, all their support, and interesting discussions on many 
aspects of life.  
John and Perry for demonstrating a different view of life, for all the delicious 
meals, for introducing me to the English pub life, and for keeping me sane. Thank 
you for your friendship, I enjoyed living with you! 
My father, Jürgen, his wife, Karin, my brothers, Elmar and Malte, for their 
constant support and love, my grandmother in Nienburg for always believing in me, I 
am missing your encouraging words and wisdom; and my grandmother in 
Braunschweig, who, when she keeps her fingers crossed, can get you through any 
obstacle in life. 
 
 
CONTENTS 
 
ABSTRACT  
ACKNOWLEDGEMENTS 
LIST OF ORIGINAL PUBLICATIONS 1 
ABBREVIATIONS 2 
1 INTRODUCTION 4 
2 REVIEW OF THE LITERATURE 7 
2.1 Cardiac diseases in dogs 7 
2.2 Cardiac remodelling 8 
2.2.1 Cardiac extracellular matrix 8 
2.2.2 Neurohormonal activation in cardiac diseases 9 
2.3 Role of inflammation in cardiac diseases 15 
2.3.1 Cytokines 16 
2.3.1.1 Pro-inflammatory cytokines 17 
2.3.1.2 Anti-inflammatory cytokines 18 
2.3.2 Growth differentiation factor 15 18 
2.4 Extracellular Matrix remodelling in cardiac diseases 19 
2.4.1 Matrix metalloproteinases and their inhibitors 20 
2.4.2 Lysyl oxidase 21 
2.5 Role of leptin in cardiac inflammation and remodelling 22 
2.6 Cardiac inflammation and remodelling in the dog 23 
2.7 Effect of systemic, non-cardiovascular diseases on cardiac 
inflammation and remodelling 25 
3 AIMS OF THE STUDY 27 
4 MATERIAL AND METHODS 28 
4.1 Dogs with cardiac diseases (18 dogs) 28 
4.2 Dogs with systemic diseases (10 dogs) 30 
4.3 Healthy control dogs (16 dogs) 32 
 
 
4 METHODS 34 
4.4 Circulating markers of inflammation and ECM remodelling 34 
4.5 Myocardial markers of inflammation and ECM remodelling 35 
4.6 PCR analysis of blood and myocardium (I-IV) 35 
4.6.1 Primer design (I-IV) 35 
4.6.2 RNA isolation  37 
4.6.2.1 RNA isolation from blood samples (I, IV) 37 
4.6.2.2 RNA isolation from myocardial samples (II-IV) 38 
4.6.3 Synthesis of cDNA (I-IV) 39 
4.6.4 Quantitative PCR (I-IV) 40 
4.7 Histological examination (II-IV) 40 
4.8 Statistical analysis  41 
5 RESULTS 43 
5.1 Dogs included in studies I-IV 43 
5.2 Pathological changes in the hearts of dogs with cardiac  
and systemic diseases (II-IV) 43 
5.3 Role of inflammation in dogs with cardiac  
and systemic diseases (I, II) 44 
5.3.1 Circulating markers of inflammation in dogs  
with cardiac diseases (I) 44 
5.3.2 Myocardial markers of inflammation in dogs  
with cardiac and systemic diseases (II) 45 
5.4 Role of ECM remodelling in dogs with cardiac  
and systemic diseases (I, III) 48 
5.4.1 Circulating markers of ECM remodelling in dogs  
with cardiac diseases (I) 48 
5.4.2 Myocardial markers of ECM remodelling in dogs  
with cardiac and systemic diseases (III) 49 
5.5 Role of leptin in dogs with cardiac diseases (IV) 51 
5.5.1 Circulating and myocardial markers leptin transcription  
in dogs with cardiac and systemic diseases (IV) 51 
  
 
 
6 DISCUSSION 53 
6.1 Markers of inflammation and ECM remodelling in dogs  
with cardiac diseases 53 
6.2 Markers of inflammation and ECM remodelling in dogs  
with systemic diseases 56 
6.3 Constitutive transcription of markers of inflammation  
and ECM remodelling in healthy control dogs 57 
6.4 Leptin in cardiac and systemic diseases 59 
6.5 Limitations of the studies 60 
6.6 Implications for further studies 60 
7 CONCLUSIONS 62 
8 REFERENCES 63 
9 PAPERS I-IV 80 
 
 
 
 
 
 
1 
 
LIST OF ORIGINAL PUBLICATIONS 
 
This thesis is based on the following publications: 
 
I Increased blood mRNA expression of inflammatory and anti-fibrotic markers in 
dogs with congestive heart failure. Fonfara S., Tew SR., Cripps P., Dukes-
McEwan J., Clegg PD. Res Vet Sci 2012 93 (2): 879-885. 
II Myocardial cytokine expression in dogs with systemic and naturally occurring 
cardiac diseases. Fonfara S., Hetzel U., Tew SR., Cripps P., Dukes-McEwan 
J., Clegg PD. Am J Vet Res 2013, 74: 408-416 
III Expression of matrix metalloproteinases, their inhibitors, and lysyl oxidase in 
myocardial samples from dogs with end-stage systemic and cardiac diseases. 
Fonfara S., Hetzel U., Tew SR., Cripps P., Dukes-McEwan J., Clegg PD. Am J 
Vet Res 2013, 74: 216-223. 
IV Leptin expression in dogs with cardiac disease and congestive heart failure. 
Fonfara S., Hetzel U., Tew SR., Dukes-McEwan J., Cripps P., Clegg PD. J Vet 
Intern Med 2011 25 (5): 1017-24. 
 
The publications are referred to in the text by their roman numerals. 
 
 
2 
 
ABBREVIATIONS 
A II Angiotensin II 
ADAM A disintegrin and metalloproteinase 
AS Aortic stenosis 
BCS Body condition score 
CAMkinase Calcium-calmodulin dependent protein kinase  
CBC Complete blood count 
CHF Congestive heart failure 
CHIEF Canine Heart Failure International Expert Forum 
DCM Dilated cardiomyopathy 
DVD Degenerative valvular disease 
ECG Electrocardiography 
ECM Extracellular matrix 
ET Endothelin-1 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GDF-15 Growth differentiation factor 15 
HE  Haematoxylin-eosin 
i.e. id est 
IFN Interferon 
IL Interleukin 
IP3 Inositol 1,4,5-triphosphate 
IVS  Interventricular septum 
LA Left atrium 
LV Left ventricle 
Lox Lysyl oxidase 
MAPkinase Mitogen-activated protein kinase 
MMP Matrix metalloproteinases 
MT-MMP Membrane-type MMP 
NFAT Nuclear factor of activated T cells 
NF-κB  Nuclear factor κ-B 
NP Natriuretic peptides  
PDA Patent ductus arteriosus 
PS Pulmonic stenosis 
RA  right atrium 
RAAS Renin-angiotensin-aldosterone-system 
RT Room temperature 
RV Right ventricle 
Smad  Sma- and mad-related proteins 
SNS Sympathetic nervous system 
STAT Signal transduction and activators of transcription 
3 
 
TACE TNF-α convertase 
TD Tricuspid valve dysplasia 
TGF Transforming growth factor  
Th T helper 
TIMP Tissue inhibitors of metalloproteinases 
TNF Tumour necrosis factor 
Treg T regulatory cells 
VSD Ventricular septal defefct 
 
 
4 
 
1 INTRODUCTION 
Cardiac remodelling is associated with a change in left ventricular geometry and 
occurs in response to haemodynamic changes in cardiac diseases. Remodelling is 
an adaptation to volume or pressure overload and presents as eccentric or 
concentric hypertrophy, depending on the cardiac disease (Weber et al., 1992; 
Valgimigli et al., 2001; Opie et al., 2006). An important component in this process is 
the cardiac extracellular matrix (ECM), which is responsible for normal left ventricular 
geometry and therefore coordinated left ventricular pump function (Weber, 1989; 
Weber et al., 1994; Spinale, 2007). 
In human medicine, involvement of inflammatory processes in cardiac diseases 
has been reported (Levine et al., 1990; Mann, 2002; Anker and von Haehling, 2004). 
Cardiac diseases are associated with cardiomyocyte injury and activation of the 
neurohormonal system, which both initiate an inflammatory reaction (Opie, 2002; 
Anker and von Haehling, 2004; Oyama, 2009; Frangogiannis, 2012). Cytokines are 
important mediators of inflammation. By activating enzymes, such as matrix 
metalloproteinases (MMP) and their inhibitors (tissue inhibitors of 
metalloproteinases; TIMP), responsible for ECM degradation and deposition, 
respectively, cytokines are involved in cardiac remodelling (Tsuruda et al., 2004; 
Graham et al., 2008). Initially, these processes result in degradation of the normal 
ECM and removal of degenerate cells, which is essential for the resolution of 
inflammation and the transition to myocardial repair (Dobaczewski et al., 2010; 
Frangogiannis, 2012). However, with progression of disease, ECM degradation with 
ventricular dilatation and systolic dysfunction or an increased ECM deposition with 
ventricular hypertrophy, increased ventricular stiffness and diastolic dysfunction 
occurs (Weber et al., 1994; Thomas et al., 1998; Kim et al., 2000; Spinale, 2007).  
Little is known about the pathogenesis of cardiac remodelling in dogs with cardiac 
diseases. Several recent studies investigated the pathological changes in the valves 
and the expression of mediators of ECM remodelling in dogs with naturally occurring 
degenerative valvular disease (DVD) and in experimental settings (Aupperle et al., 
2008; Disatian et al., 2008; Aupperle et al., 2009a; Disatian and Orton, 2009; 
Aupperle and Disatian, 2012; Lacerda et al., 2012; Orton et al., 2012; Han et al., 
2013). However, these studies did not investigate the myocardium and only very few 
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studies exist that investigate other cardiac diseases (Kukielka et al., 1995; Gilbert et 
al., 1997; Basso et al., 2004; Oyama and Chittur, 2005; Tidholm and Jonsson, 2005; 
Lobo et al., 2010).  
Leptin, an adipocytokine, was reported to play a role in cardiac diseases in 
people (Filippatos et al., 2000; Schulze et al., 2003; Schulze and Kratzsch, 2005; 
Karmazyn et al., 2007). It contributes to a systemic inflammatory state by increasing 
the levels of circulating catecholamines and inflammatory cytokines (Haynes et al., 
1997b; Loffreda et al., 1998; Filippatos et al., 2000). The relevance of obesity for 
human cardiovascular disease is well known, and also in dogs obesity is an 
increasing problem (German et al., 2010). Elevated leptin levels are reported in 
obese dogs and an association of obesity with ventricular hypertrophy and cardiac 
dysfunction has been suspected (Ishioka et al., 2002; German et al., 2010; Mehlman 
et al., 2013). However, the potential role of leptin on myocardial inflammation and 
remodelling in dogs is not known.  
Myocardial impairment has been reported in people and dogs with systemic 
diseases (Parker et al., 1984; Nelson and Thompson, 2006; Merx and Weber, 2007; 
Serra et al., 2010; Langhorn et al., 2013). Despite a high awareness of the effect of 
systemic diseases in the heart in human medicine, studies investigating cardiac 
function and myocardial inflammation in veterinary patients are sparse (Nelson and 
Thompson, 2006; Langhorn et al., 2013). An increase in troponin I consistent with 
myocardial cell damage is reported in dogs with systemic diseases (Serra et al., 
2010; Langhorn et al., 2013). However, whether cardiac remodelling occurs in these 
patients is not known. 
A better understanding of cardiac inflammation and remodelling and the 
identification of circulating biomarkers would be helpful for the clinical management 
and the assessment of prognosis in dogs with cardiac and also systemic diseases. 
Biomarkers for congestive heart failure and cardiomyocyte damage exist in dogs and 
single studies reported circulating cytokines and MMP in dogs with DVD and 
systemic diseases (Oyama et al., 2009; Fonfara et al., 2010; Ljungvall et al., 2011; 
Zois et al., 2012; Langhorn et al., 2013). However, studies investigating mRNA levels 
of markers of inflammation and ECM remodelling in the blood and myocardium of 
dogs with other cardiac or with systemic diseases are very fragmentary (Kukielka et 
al., 1995; Oyama and Chittur, 2006). Furthermore, the role of leptin in cardiac 
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inflammation and remodelling might be of importance considering the increase of 
obesity in the canine population. 
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2 REVIEW OF THE LITERATURE 
2.1 Cardiac diseases in dogs 
Cardiac diseases are frequent in dogs and progression into heart failure is a 
common cause for morbidity and mortality in this species. Cardiac diseases are 
either present at birth, congenital cardiac diseases, or develop during adulthood, 
acquired cardiac diseases. The most common congenital cardiac diseases are aortic 
stenosis (AS), pulmonic stenosis (PS), patent ductus arteriosus (PDA), ventricular 
septal defect (VSD) and tricuspid valve dysplasia (TD; Tidholm, 1997; Oliveira et al., 
2011). These diseases affect either the function of a valve, obstruct cardiac output or 
led to connections between the systemic and pulmonary circulation. As a 
consequence, they cause volume or pressure overload of the heart with subsequent 
cardiac adaptation, which involves remodelling of the extracellular matrix (ECM; see 
chapter 2.2).  
Common acquired cardiac diseases in dogs are degenerative valvular disease 
(DVD) and dilated cardiomyopathy (DCM) (Serfass et al., 2006; Martin et al., 2009; 
Wess et al., 2010). DVD is generally caused by progressive myxomatous 
degeneration of the atrioventricular valves and accounts for 75–80% of canine 
cardiac diseases (Borgarelli and Buchanan, 2012; Fox, 2012). Its prevalence is 
strongly age-related and dogs of small to medium size breeds are most commonly 
affected, with some breeds, such as Cavalier King Charles Spaniels, Dachshunds 
and Chihuahuas, being over-represented (Borgarelli and Buchanan, 2012). In 
contrast, DCM is a primary myocardial disease that is characterised by cardiac 
enlargement, impaired systolic and diastolic function and, in some breeds, 
ventricular arrhythmias. It is a disease of large- and medium sized breed dogs and 
Doberman pinschers, Newfoundlands and Great Danes are overrepresented 
(Tidholm et al., 2001a; Martin et al., 2009). Although canine DCM is described as 
one disease, it varies in the presenting complaint, clinical evaluation, and rate of 
progression (Serfass et al., 2006; Martin et al., 2009; Wess et al., 2010). A familial 
form of DCM has been identified in several breeds and is suspected in others 
(Tidholm et al., 2001a; Martin et al., 2009; Wess et al., 2010).  
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Genetic causes are reported for several cardiac diseases, but in many the cause 
is unknown (Noutsias et al., 2002; Maron et al., 2006; Elliott et al., 2008; Werner et 
al., 2008; Madsen et al., 2011; Mausberg et al., 2011; Meurs et al., 2012). It is 
suspected that cardiac inflammation and remodelling play a role in development and 
observed variations of cardiac diseases. Haemodynamic abnormalities associated 
with cardiac diseases will further contribute to ECM remodelling and progression of 
disease. 
2.2 Cardiac remodelling 
Cardiac diseases are associated with cardiac remodelling, which is a disease-
induced change in the composition and function of the heart. To specify, cardiac 
remodelling has recently been defined as ‘molecular, cellular, interstitial and genomic 
changes, which are manifested clinically as changes in size, shape and function of 
the heart following cardiac injury’ (Valgimigli et al., 2001). The process is influenced 
by haemodynamic load, neurohormonal activation and other factors still under 
investigation. Components involved in the remodelling process are cardiomyocytes, 
the interstitium, fibroblasts, collagen and the vasculature (Weber et al., 1992; 
Valgimigli et al., 2001; Opie, 2002; Anker and von Haehling, 2004).  
2.2.1 Cardiac extracellular matrix 
The myocardium represents the main component of the heart and is comprised of 
cardiomyocytes and connective tissue. Although the myocytes represent most of the 
myocardial mass, they account for only approximately 30-40% of the cell number, 
and vascular smooth muscle cells, endothelial cells and fibroblasts together 
represent the majority (Nag, 1980; Weber, 1989; Banerjee et al., 2007). Fibroblasts 
produce and maintain the connective tissue fibre network, the ECM, which 
contributes to the tensile strength and stiffness of the heart (Weber, 1989; Weber et 
al., 1994; Spinale, 2002, 2007). 
The ECM consists of a structural network of interstitial collagens to which other 
matrix components are attached. In mammalian species, 85% of the myocardial 
collagen is type I collagen and 11% is type III collagen (Weber, 1989; Weber et al., 
1994). The remaining components are collagens type IV, V and VI, elastin, the 
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glycoproteins laminin and fibronectin, glycosaminoglycans and proteoglycans 
(Spinale, 2002, 2007). Apart from fibroblasts, the myocardium has other non-
myocytic resident cells, namely macrophages and mast cells; these are the source of 
cytokines and growth factors (Nag, 1980; Stewart et al., 2003). Transmembrane 
proteins, such as integrins and membrane bound matrix metalloproteinases, enable 
cell to cell communication (Giancotti and Ruoslahti, 1999; Ross, 2002; Ottaviano and 
Yee, 2011).  
The cardiac ECM is critical for the maintenance of the structural integrity of the 
heart. It translates the force that is generated by the myocytes into an organised 
ventricular contraction and prevents myofibre slippage (Weber, 1989; Weber et al., 
1990; Spinale, 2002, 2007). Furthermore, it affects cell development, proliferation, 
migration and adhesion, is a reservoir for ECM signalling molecules and is involved 
in cell to cell signalling (Ross, 2002; Souders et al., 2009). Therefore, the ECM plays 
an important role in ventricular geometry and function. Accordingly, in cardiac 
diseases not only cardiomyocyte abnormalities, but also inadequate ECM 
remodelling processes are important causes for cardiac dysfunction (Weber, 1989; 
Weber et al., 1990; Spinale, 2002, 2007) 
2.2.2 Neurohormonal activation in cardiac diseases  
During progression of cardiac diseases, the myocardium adapts to volume or 
pressure overload, depending on the underlying disease. Initially, it compensates for 
the primary defect, before the stage of overt myocardial failure. Myocardial 
contractile failure is the consequence of different initiating mechanisms, i.e. pressure 
overload in AS and PS, volume overload in PDA, TD and DVD, primary myocardial 
damage in myocarditis, cardiomyopathy and myocardial infarction (Valgimigli et al., 
2001; Opie, 2002). Although the aetiologies of these diseases are different, they 
share several pathways in terms of molecular, biochemical and mechanical 
processes that cause cardiac remodelling and are involved in progression of cardiac 
disease (Valgimigli et al., 2001; Opie, 2002; Tsuruda et al., 2004).  
Myocardial failure results in inadequate cardiac output and, therefore, low blood 
pressure and decreased end-organ perfusion (Valgimigli et al., 2001; Opie, 2002). 
This is sensed by baro-, mechano- and chemoreceptors and leads to the activation 
of interrelated neuroendocrine systems, as an attempt to maintain the circulation and 
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normal organ perfusion. Involved are the sympathetic nervous system (SNS), the 
renin-angiotensin-aldosterone-system (RAAS), vasopressin, endothelin-1 (ET), 
natriuretic peptides (NP) and cytokines (Valgimigli et al., 2001; Opie, 2002; Anker 
and von Haehling, 2004; Oyama, 2009).  
Noradrenalin, the main neurotransmitter of the SNS, stimulates cardiac beta 1-
receptors located on the sinus and atrioventricular nodes, conducting cells and 
cardiomyocytes, which results in increased cardiac chrono-, dromo-, lusi- and 
inotropy; stimulation of peripheral alpha-receptors located on vascular smooth 
muscle cells results in peripheral vasoconstriction (Katz, 2011). This improves 
cardiac output and stabilises the blood pressures, however, tachycardia and 
increased afterload increase the work for the heart and thereby the myocardial 
oxygen demand and energy expenditure. Furthermore, beta 1-receptor stimulation 
leads to increased intracellular calcium levels. Cytosolic calcium overload is 
associated with early and late afterdepolarisations, which are an important cause of 
premature systoles and tachycardias. Furthermore, calcium contributes to cardiac 
remodelling via calmodulin and calcineurin activating nuclear transcription factors, 
i.e. nuclear factor κ-B (NF-κB) and nuclear factor of activated T-cells (NFAT; Fig. 1; 
Opie, 2002; Oyama, 2009; Katz, 2011). 
Reduced renal perfusion and renal beta-receptor stimulation activates the RAAS. 
Angiotensin (AT) II causes decreased fluid excretion, is a potent peripheral 
vasoconstrictor and stimulates the secretion of aldosterone, catecholamines, 
vasopression and ET (Opie, 2002; Oyama, 2009; Katz, 2011). Furthermore, AT II 
contributes to proliferative and inflammatory responses via activation of AT1-
receptors on cardiomyocytes and cardiac fibroblasts, causing activation of 
phospholipase C and mitogen-activated protein (MAP) kinase pathways (Fig. 1) (Duff 
et al., 1995; Paradis et al., 2000). Stimulation of central AT1-receptors results in an 
increased sympathetic outflow. Aldosterone acts on renal tubules to increase sodium 
reabsorption and excretion of potassium and hydrogen ions, thereby increasing the 
blood volume. However, in addition, aldosterone stimulates cardiac fibrosis and 
promotes maladaptive proliferative responses (Fig. 1; Oyama, 2009; Katz, 2011).  
The release of vasopressin as the major regulator of the body’s water balance 
causes increased water reabsorption by the kidney through the binding of 
vasopressin to its receptor V2 on the basolateral membrane of the principal cells in 
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the collecting ducts (Nonoguchi et al., 1995). Activation of V2 results in 
phosphorylation of aquaporin and translocation of the phosphorylated protein to the 
luminal membrane where it forms water-permeable channels that increase the water 
influx (Nielsen et al., 1995). Vasopressin also increases thirst via V1a-receptors on 
neurons in the supraoptic and paraventricular nuclei of the hypothalamus. V1-
receptors on vascular smooth muscle cells and cardiomyocytes stimulate G protein 
G
αq, which results in phospholipase C induced release of inositol 1,4,5-triphosphate 
(IP3) and diacylglycerol, an increase of cytosolic calcium and, subsequently, 
activation of calcium-calmodulin dependent protein kinases (CAMkinases) and 
calcineurin (Gopalakrishnan et al., 1991; Xu and Gopalakrishnan, 1991; Briner et al., 
1992). This results in vasoconstriction and activation of several transcription factors 
(NF-κB, NFAT) in cardiomyocytes and therefore pathological cardiac hypertrophy 
(Fig. 1; Katz, 2011).  
Endothelin-1 binds to ETA- and ETB-receptors. Both receptor types are present on 
cardiomyocytes and vascular smooth muscle cells (Ito et al., 1993; Pollock et al., 
1995). Stimulation of ETA-receptors results in increased myocardial contractility and 
vasoconstriction via G protein G
αq and phospholipase C activation (Pollock et al., 
1995). It also stimulates proliferation via the activation of several MAPkinase 
pathways (Fig. 1; Ito et al., 1993; Yamazaki et al., 1996). The response to ET via 
binding to the ETA-receptor dominates over that evoked by binding to the counter-
regulatory ETB-receptors (Katz, 2011).  
Natriuretic peptides, atrial and brain NP, inhibit the sympathetic nervous system, 
the RAAS and ET release and are therefore counter regulatory to the above 
mentioned mechanisms (Fujisaki et al., 1995; Levin et al., 1998; Brunner-La Rocca 
et al., 2001; Potter et al., 2006). NP are released by atrial cardiomyocytes in 
response to atrial stretch and by ventricular cardiomyocytes in heart failure and bind 
to specific receptors, NP receptors A and B, which can be found in cardiomyocytes, 
fibroblasts and endothelial cells in the heart, and in several other organs (de Bold et 
al., 1981; Levin et al., 1998; Magga et al., 1998; Yamane et al., 2011). NP receptors 
are G protein coupled receptors synthesising cyclic guanine monophosphate and 
stimulating protein kinase G, which results in reduced intracellular calcium release 
and attenuated MAPkinase activity and therefore inhibition of cellular hypertrophy 
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and proliferation (Fig. 1; Potter et al., 2006). However, the beneficial effects of NP 
are markedly blunted in heart failure (Levin et al., 1998).  
The neurohormonal activation in cardiac diseases improves cardiac function and 
stabilises blood pressure, however, this occurs at the expense of increased cardiac 
work (increased pre- and afterload), intracellular calcium imbalances, proliferative 
responses and endothelial cell and cardiomyocyte membrane damage (Valgimigli et 
al., 2001; Opie, 2002; Anker and von Haehling, 2004; Katz, 2011). As a result, the 
myocardial oxygen demand increases and defects in the myocardial contraction-
relaxation cycle, arrhythmia and myocardial dysfunction develop (Valgimigli et al., 
2001; Opie, 2002; Martin et al., 2009; Katz, 2011).  
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Figure 1: Simplified signal transduction in cardiac remodelling.  
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AII: Angiotensin II, AC: Adenylyl cyclase, ATP: Adenosine triphosphate, Beta-R: 
Betareceptor, Ca: Calcium, cAMP: Cyclic adenosine monophosphate, cGMP: Cyclic 
guanosine monophosphate, CREB: Cyclic AMP receptor element-binding protein, 
DAG: Diacylglycerol, ECM: Extracellular matrix, ERK: Extracellular receptor kinase, 
ET: Endothelin-1, G: Monomeric G protein, GC: Guanylyl cyclase, G-R: GTP binding 
protein coupled receptor, GTP: Guanosine triphosphate, IP3: Inositol 1,4,5-
triphosphate, JAK: Janus kinase, MAPK: Mitogen activated protein kinase, MMP: 
Matrix metalloproteinase, MR: Mineralocorticoid receptor, NE: Noradrenalin, NFAT: 
Nuclear factor of activated T cells, NFκB: Nuclear factor κ-B, NO: Nitric oxide, NPR: 
Natriuretic peptide receptor, PIP2: Phosphatidylinositol 4,5-biphosphate, PKA: 
Protein kinase A, PKC: Protein kinase C, PKG: Protein kinase G, PLB: 
Phospholamban, PLC: Phospholipase C, Ras: ‘Rat sarcoma’, RYR: Ryanodine 
receptor, SERCA: Sarcoplasmic reticulum Ca-ATPase, sGC: Soluble guanylyl 
cyclase, SMAD: Sma and Mad related family, SR: sarcoplasmic reticulum, STAT: 
Signal transducer and activator of transcription, TGFR: Transforming growth factor 
beta receptor, R: Receptor, TIMP: Tissue inhibitor of matrix metalloproteinase. 
 
Myocardial hypertrophy is an adaptation to volume or pressure overload. 
Myocardial stretch, the hormones mentioned above, cytokines and growth factors 
released due to cardiomyocyte damage as well as neurohormonal stimulation 
contribute to myocardial hypertrophy and fibrosis (Weber et al., 1994; Opie, 2002; 
Chatterjee, 2005; Heineke and Molkentin, 2006). In physiological amounts collagen 
might help to limit ventricular dilatation, but an increased proportion results in 
excessive chamber stiffness and diastolic dysfunction (Spinale et al., 1991; Weber et 
al., 1994; Spinale, 2002, 2007). On the other hand, increased collagen degradation 
results in myocyte slippage and cardiac chamber dilatation, thereby, it can cause 
systolic dysfunction and ventricular rupture (Weber et al., 1994; Spinale et al., 1996; 
Thomas et al., 1998; Ducharme et al., 2000; Kim et al., 2000; Spinale, 2002, 2007). 
Apart from the alteration of fibrous elements of the ECM, cardiac remodelling 
involves cellular remodelling, i.e. changes in cardiomyocyte size and shape (Opie et 
al., 2006; Dobaczewski et al., 2010; Frangogiannis, 2012; Koitabashi and Kass, 
2012). Progressive cardiac remodelling results therefore in ventricular hypertrophy or 
dilatation, deforms left ventricular geometry and impairs cardiac function. However, 
the precise molecular mechanisms that underlie the transformation from 
compensated left ventricular hypertrophy to pathological remodelling and cardiac 
failure remain incompletely understood.  
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2.3 Role of inflammation in cardiac diseases 
Several studies report on the role of the immune system and ECM remodelling in 
the progression of cardiac diseases (Levine et al., 1990; Spinale, 2002; Anker and 
von Haehling, 2004; Spinale, 2007; Chen et al., 2008; Graham et al., 2008). 
Myocarditis, but also myocardial infarction, inflammatory DCM as well as heart 
failure with reduced or normal ejection fraction are associated with inflammatory 
processes in the myocardium (Levine et al., 1990; Anker and von Haehling, 2004; 
Maron et al., 2006; Dobaczewski et al., 2010; Frangogiannis, 2012). It is commonly 
believed that besides an activation of neurohormones, pro-inflammatory cytokines 
contribute to the progression of heart failure, therefore, the latter is now regarded as 
a state of chronic inflammation (Pagani et al., 1992; Anker and von Haehling, 2004; 
Chen et al., 2008; von Haehling et al., 2009; Hedayat et al., 2010; Tamariz and Hare, 
2010). Cardiac inflammation is associated with myocardial infiltration of inflammatory 
cells, the production of cytokines, endothelial cell activation and myocardial cell 
damage and degeneration (Mann, 2002; Anker and von Haehling, 2004; Wei, 2011; 
Frangogiannis, 2012). In people with DCM and congestive heart failure (CHF), 
activation of endothelial cells with upregulation of endothelial cell adhesion 
molecules induces recruitment of inflammatory cells, such as macrophages, 
neutrophils and lymphocytes, into the myocardium (Devaux et al., 1997; Noutsias et 
al., 1999; Noutsias et al., 2002; Noutsias et al., 2003; Anker and von Haehling, 2004; 
Wei, 2011). These cells are involved in initiating cardiac regeneration and repair. 
Alongside damaged myocardial cells, cells of the ECM, i.e. fibroblast, mast cells and 
infiltrating inflammatory cells, contribute to the production of cytokines and growth 
factors (Nag, 1980; Stewart et al., 2003; Souders et al., 2009; Wei, 2011; 
Frangogiannis, 2012). However, control of the inflammatory state by anti-
inflammatory and pro-fibrotic factors is crucial.  
Different populations of T helper (Th) subpopulations are reported to play a role in 
progression of cardiac diseases. Four major lineages, Th1, Th2, Th17 and T 
regulatory (Treg) cells are known (Mosmann et al., 1986; Aggarwal et al., 2003; Zhu 
et al., 2010). These T cell subsets are involved in fibrosis in chronic cardiac injury, 
while Th2 polarised responses promote fibrosis, Th1 cells might be anti-fibrogenic 
(Marra et al., 2009; Wei, 2011). Inflammatory events trigger a Th1 response and Th1 
cytokines are believed to participate in the initiation of fibrosis, whereas the chronic 
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disease processes are usually driven by a Th2 response, resulting in fibroblast 
activation and proliferation, myofibroblast differentiation and ECM accumulation. In 
human heart failure patients, an immune response of Th1 predominance and 
Th1/Th2 imbalance has been reported (Cheng et al., 2009). Th17 cells are involved 
in the initiation or progression of inflammatory diseases, promoting degradation of 
type I and type III collagens and contributing to myocardial fibrosis (Feng et al., 
2009; Wei, 2011). On the other hand, Treg cells constitute an anti-inflammatory and 
pro-fibrotic lineage of T cells that secrete IL-10 and TGF-β (Huber et al., 2006; Wei, 
2011; Tang et al., 2012). However, Treg cells might also be involved in limitation of 
fibrogenesis, since they can suppress an excessive immune activation (Kvakan et 
al., 2009). Depending on the primary insult, the underlying condition and the 
activated cell populations cardiac regeneration and repair or a progressive cardiac 
disease can develop.  
2.3.1 Cytokines 
In cardiac disease, cytokines are produced by resident myocardial cells, such as 
damaged cardiomyocytes, fibroblasts, mast cells, and infiltrating inflammatory cells, 
for example macrophages and T cells (Kuhl et al., 1996; Noutsias et al., 2002). 
Cytokines are highly potent endogenous mediators of intercellular communication 
(Klesius, 1982; Trotta, 1991). They bind to specific receptors and act as gene-
regulatory proteins through the activation of transcription factors, such as NF-κB, 
sma- and mad-related proteins (Smad) and signal transduction and activators of 
transcription (STAT) proteins (Schutze et al., 1992; Briscoe and Guschin, 1994; 
Nakao et al., 1997; Anker and von Haehling, 2004).  
Based on their effect, cytokines were originally classified as pro- and anti-
inflammatory. The pro-inflammatory cytokines of highest relevance in the 
progression of CHF in humans and in animal models are interleukin (IL)-1, IL-6, IL-8 
and tumour necrosis factor (TNF)-α, whereas IL-10 and transforming growth factor 
(TGF)-β, for example, are anti-inflammatory cytokines and considered to be 
cardioprotective (Pagani et al., 1992; TorreAmione et al., 1996; Bolger et al., 2002; 
Chen et al., 2008; von Haehling et al., 2009). Their different cytokine expression 
patterns characterise Th subpopulations, Th1 cells produce IFN-γ, whereas Th2 cells 
produce IL-4, IL-5 and IL-13 and Th17 cells produce IL-17, IL-21, IL-22 (Mosmann et 
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al., 1986; Aggarwal et al., 2003; Zhu et al., 2010). Treg cells can be differentiated 
into Treg type 1 cells which secrete IL-10, and Th3 cells which secrete TGF-β (Huber 
and Schramm, 2006; Wei, 2011; Tang et al., 2012).   
2.3.1.1 Pro-inflammatory cytokines  
The role of IL-1, IL-6 and TNF-α in human cardiac diseases has been studied 
extensively. Elevated circulating and myocardial levels were found in patients with 
various cardiac diseases and in CHF and have been correlated to disease severity 
and mortality (TorreAmione et al., 1996; Deswal et al., 2001b; Torre-Amione, 2005; 
von Haehling et al., 2009). Pro-inflammatory cytokines have negative inotropic 
effects, which are mediated through down-regulation of cardiac beta-receptors, 
myocardial nitric oxide production and impaired myocardial energy production (Finkel 
et al., 1992; Pagani et al., 1992; Zell et al., 1997). These cytokines play a role in 
cardiac remodelling by activating transcription factors and stimulating enzymes 
involved in ECM degradation and deposition (Sivasubramanian et al., 2001; 
Bradham et al., 2002b; Siwik and Colucci, 2004). Furthermore, they stimulate the 
expression of adhesion molecules, activate inflammatory cells and contribute to the 
production of cytokines and reactive oxygen species, which maintain the 
inflammatory process (Kukielka et al., 1993; Braun et al., 1995; Kukielka et al., 1995; 
Deswal et al., 2001a; Yndestad et al., 2003; Torre-Amione, 2005; Castellano et al., 
2008; Chen et al., 2008; Hedayat et al., 2010; Zhang et al., 2011). The resulting 
myocardial impairment, cardiac remodelling and persistent inflammatory response 
are suspected to contribute to the progression of CHF. The harmful effects of pro-
inflammatory cytokines and the increased levels in patients with CHF were the 
rationale behind several clinical trials that blocked TNF-α in human heart failure 
patients (reviewed by Pagani et al., 1992; Mann, 2002). However, the results of 
these trials were disappointing, since no improvement of clinical signs and reduced 
survival times were observed (Anker and von Haehling, 2004; Torre-Amione, 2005; 
Chen et al., 2008). This suggests that pro-inflammatory cytokines do not only exert 
detrimental effects, but might also be involved in cardiac regeneration in patients 
with CHF (Chen et al., 2008; Hedayat et al., 2010). 
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2.3.1.2 Anti-inflammatory cytokines  
Anti-inflammatory cytokines, such as IL-10 and TGF-β, inhibit pro-inflammatory 
cytokines (Tsunawaki et al., 1988; de Waal Malefyt et al., 1991; Bolger et al., 2002; 
Anker and von Haehling, 2004; Kaur et al., 2009). IL-10 is capable of down-
regulating numerous inflammatory pathways by suppressing cytokine, adhesion 
molecule and matrix metalloproteinase production and by regulating growth and 
differentiation of lymphocytes (Fiorentino et al., 1991; Mosmann, 1994; Song et al., 
1997; Moore et al., 2001; Anker and von Haehling, 2004; Frangogiannis, 2012). 
TGF-β is a powerful immunosuppressive and profibrotic cytokine (Edwards et al., 
1987; Dobaczewski et al., 2011; Kapur, 2011). It inhibits pro-inflammatory cytokine 
and endothelial cell adhesion molecule expression and thereby reduces the rolling 
and emigration of neutrophils and lymphocytes (Gamble and Vadas, 1988, 1991; 
Smith et al., 1996; Frangogiannis, 2012). TGF-β has three isoforms, TGF-β1-3. Of 
these, TGF-β1 and TGF-β3 are major stimulators of fibroblasts during normal ECM 
homoeostasis and tissue repair (Lim and Zhu, 2006; Creemers and Pinto, 2011; 
Dobaczewski et al., 2011). In cardiac diseases, they are considered to play a role in 
the resolution of inflammation and the transition to fibrosis. However, by inducing 
fibrosis and cardiomyocyte hypertrophy TGF-β promotes the structural remodelling 
of the heart and might therefore contribute to systolic and diastolic dysfunction in 
cardiac diseases (Nakao et al., 1997; Song et al., 1997; Lim and Zhu, 2006; 
Creemers and Pinto, 2011; Dobaczewski et al., 2011; Westermann et al., 2011; 
Frangogiannis, 2012). TGF-β2 is important for the fetal development of the heart and 
might be involved in activation of the fetal gene programme in the failing myocardium 
(Lim and Zhu, 2006). 
2.3.2 Growth differentiation factor 15 
Growth differentiation factor 15 (GDF-15), a member of the TGF-β superfamily, 
regulates inflammatory and apoptotic pathways needed for tissue development, 
differentiation and repair (Kempf and Wollert, 2009). A weak basal expression of 
GDF-15 is present in most tissues, with a marked increase in its expression in 
response to tissue injury and inflammation (Kempf and Wollert, 2009). In the heart, 
GDF-15 is produced by cardiomyocytes, endothelial cells, smooth muscle cells, 
adipocytes and macrophages (Kempf and Wollert, 2009) and is used as a biomarker 
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for disease progression and prognosis in people with acute and chronic heart failure 
(Kempf et al., 2007; Kempf and Wollert, 2009; Lok et al., 2012). In myocardial 
ischaemia, GDF-15 is considered to exert a protective role, because of its anti-
apoptotic and anti-inflammatory effects. It might also be involved in cardiac fibrosis, 
as increased GDF-15 levels in cardiac diseases appear to correlate with the degree 
of myocardial fibrosis (Kempf et al., 2006; Kempf and Wollert, 2009; Lok et al., 
2012). Nonetheless, people with DCM have been shown to exhibit only weak 
myocardial GDF-15 mRNA and protein production (Lok et al., 2012). Canine GDF-15 
has been isolated from and characterised in an osteosarcoma cell line (Yamaguchi 
et al., 2008), but its transcription in the myocardium of healthy dogs and dogs with 
cardiac diseases has so far not been investigated. 
2.4 Extracellular matrix remodelling in cardiac diseases 
2.4.1 Matrix metalloproteinases and their inhibitors 
ECM remodelling is regulated by a family of proteolytic enzymes, the matrix 
metalloproteinases (MMP), along with their natural tissue inhibitors (tissue inhibitors 
of metalloproteinases; TIMP) (Woessner, 1991; Nagase and Woessner, 1999; 
Spinale, 2002; Visse and Nagase, 2003; Spinale, 2007; Graham et al., 2008).  
The MMP family comprises more than 25 zinc-dependent ECM-degrading 
endopeptidases that degrade the ECM under both physiological and pathological 
conditions (Visse and Nagase, 2003). There are two principal types of MMP, those 
that are secreted into the extracellular space and represent the majority of MMP 
species, and those that are membrane bound (membrane-type MMP; MT-MMP). 
The secreted MMP are synthesised and released as inactive zymogens and are 
activated by enzymatic cleavage to exert their proteolytic activity, whereas MT-MMP 
undergo intracellular activation through a pro-protein convertase pathway and are 
proteolytically active once inserted into the cell membrane (Somerville et al., 2003; 
Visse and Nagase, 2003). Activated MMP can degrade all ECM components; they 
stimulate other MMP and release growths factors (Nagase and Woessner, 1999; 
Nagase et al., 2006). Their activity is regulated by TIMP-1-4 (Gomez et al., 1997; 
Nagase and Woessner, 1999; Visse and Nagase, 2003). TIMP bind to the catalytic 
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domain of active MMP and prevent their access to substrates (Gomez et al., 1997; 
Nagase and Woessner, 1999; Visse and Nagase, 2003). TIMP-1, -2 and -4 are 
soluble, whereas TIMP-3 interacts with the ECM and might therefore exert a more 
localised, potent and prolonged effect (Gomez et al., 1997). By inhibiting MMP 
activity, TIMP prevent ECM degradation, are profibrotic and potentially anti-
inflammatory. TIMP are also involved in myofibroblast activation, increased collagen 
synthesis, fibroblast apoptosis and inhibition of angiogenesis (Gomez et al., 1997; 
Vanhoutte and Heymans, 2010). Additionally, TIMP-3 has been demonstrated to 
inhibit the a disintegrin and metalloproteinase (ADAM-17), also named TNF-α 
convertase (TACE), and might therefore have a fundamental role in the control of 
inflammation through the regulation of TNF-α signalling (Kassiri et al., 2005; 
Vanhoutte and Heymans, 2010). 
Previous studies have shown that MMP and TIMP are expressed in the 
mammalian myocardium: collagenases (MMP-1, -8, and -13), gelatinases (MMP-2 
and -9), stromelysins (MMP-3 and MMP-7), membrane-type MT1-MMP and TIMP-1-
4 have been identified in the major cell types of the normal myocardium, i.e. cardiac 
myocytes, fibroblasts, smooth muscle cells and endothelial cells (Woessner, 1991; 
Spinale, 2002; Visse and Nagase, 2003; Spinale, 2007; Vanhoutte and Heymans, 
2010).  
Myocardial MMP induction is influenced by mechanical stimuli, neurohormones 
(including AT II, ET, noradrenalin, corticosteroids), growth factors and cytokines, 
such as IL-1 and TNF-α (Tyagi et al., 1993; Bradham et al., 2002b; Spinale, 2002, 
2007; Tsuruda et al., 2004; Koskivirta et al., 2010; Vanhoutte and Heymans, 2010; 
Lacerda et al., 2012). TIMP-2 is constitutively expressed within the heart, whereas 
TIMP-1 and TIMP-3 are induced by pro-inflammatory cytokines (Li et al., 1999). 
During cardiac remodelling in health and disease, collagenases degrade interstitial 
type I, II and III collagens, whereas gelatinases act in particular on basement 
membranes and partially degraded collagen. Stromelysins have a broad substrate 
specificity including proteoglycans, laminin, fibronectin, gelatine and basement 
membrane collagens (Spinale, 2002; Visse and Nagase, 2003; Spinale, 2007). 
Besides matrix degradation, MMP activate other MMP (Nagase et al., 2006; 
Vanhoutte and Heymans, 2010). Increased MMP activity may result in collagen 
degradation, increased inflammatory response, ECM remodelling as well as left 
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ventricular dilatation and dysfunction (Thomas et al., 1998; Chow et al., 2007; 
Sivakumar et al., 2008). On the other hand, increased TIMP activity can result in 
excessive collagen deposition and, therefore, increased left ventricular stiffness and 
dysfunction (Spinale, 2002; Visse and Nagase, 2003; Spinale, 2007; Vanhoutte and 
Heymans, 2010). An equilibrium between deposition and degradation of ECM 
components is therefore required for efficient left ventricular geometry and cardiac 
function. Accordingly, an imbalance is a major cause of pathological ECM 
remodelling (Thomas et al., 1998; Spinale, 2002, 2007; Graham et al., 2008). In 
humans different expression patterns are reported depending on the cardiac 
disease, with increased myocardial MMP-1, MMP-2, TIMP-1 and TIMP-2 and 
variably altered MMP-9 transcription in the failing myocardium (Thomas et al., 1998; 
Siwik and Colucci, 2004; Picard et al., 2006; Batlle et al., 2007; Spinale, 2007; 
Graham et al., 2008; Sivakumar et al., 2008). 
2.4.2 Lysyl oxidase 
Lysyl oxidase (lox) is an extracellular, copper dependent amino oxidase that 
catalyses lysine-derived crosslinks between collagen and elastin, resulting in the 
deposition of insoluble collagen fibres (Smith-Mungo and Kagan, 1998). Apart from 
lox, four lox-like (loxl-1, -2, -3, -4) proteins exist (Lopez et al., 2010). In the heart, lox 
is the most abundant of the group of proteins and the only one that uses collagen as 
substrate (Lopez et al., 2010). It might also be involved in fibroblast motility and 
migration as well as the regulation of cell adhesion (Nelson et al., 1988; Giampuzzi 
et al., 2005). Lox is produced by fibroblasts and myofibroblasts and its transcription 
is stimulated by hypoxia-inducible factor-1α, TNF-α and TGF-β1 (Smith-Mungo and 
Kagan, 1998; Lopez et al., 2010; Voloshenyuk et al., 2011). Increased lox levels, 
associated with excessive fibrillar collagen cross linking and fibre deposition, have 
been reported in human patients with enhanced myocardial stiffness, left ventricular 
dysfunction and heart failure (Sivakumar et al., 2008; Lopez et al., 2009; Lopez et 
al., 2010; Kasner et al., 2011). Lox might also play an important role in atrial fibrosis 
and development of atrial fibrillation (Adam et al., 2011).  
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2.5 Role of leptin in cardiac inflammation and remodelling 
Recent studies have shown that adipose tissue is not only an energy storage 
organ, but also exerts important endocrine and immune functions (Karmazyn et al., 
2008; German et al., 2010; Sweeney, 2010; Ouchi et al., 2011). The latter are 
mediated through the release of adipocytokines, which activate neutrophils, 
monocytes and lymphocytes, thereby mediating the production of pro-inflammatory 
cytokines and promoting T helper 1 responses. Centrally, leptin activates the 
sympathetic nervous system (Loffreda et al., 1998; Karmazyn et al., 2008; Knudson 
et al., 2008; Fernandez-Riejos et al., 2010). Therefore, obesity is now considered to 
be accompanied by a systemic inflammatory state (Loffreda et al., 1998; Fernandez-
Riejos et al., 2010).  
Leptin belongs to the group of adipocytokines, which includes also resistin, 
adiponectin, visfatin and more classical cytokines, such as TNF-α, IL-1 and IL-6 
(Rondinone, 2006; Karmazyn et al., 2008). Leptin is the product of the Ob gene and 
was first shown to be secreted by white adipocytes (Zhang et al., 1994; Igel et al., 
1997). It has a profound impact on body weight control and its deficiency and 
receptor defects are associated with obesity (Zhang et al., 1994; Igel et al., 1997). 
While leptin regulates energy homoeostasis by reducing appetite and increasing the 
basal metabolic rate, obesity is associated with hyperleptinaemia, which develops 
most probably as a consequence of leptin resistance (Igel et al., 1997). Circulating 
leptin levels are correlated with pro-inflammatory cytokine levels and increased leptin 
concentrations were found in several chronic diseases, including cardiac diseases 
and CHF (Faggioni et al., 1998; Loffreda et al., 1998; Schols et al., 1999; Filippatos 
et al., 2000; Schulze et al., 2003; Schulze and Kratzsch, 2005; Conde et al., 2010; 
Fernandez-Riejos et al., 2010; Sweeney, 2010; Ouchi et al., 2011). 
In the heart, cardiomyocytes, endothelial cells and smooth muscle cells produce 
leptin and its receptor and the production is increased by AT II and ET, suggesting 
local auto- and paracrine effects (Sierra-Honigmann et al., 1998; Rajapurohitam et 
al., 2003; Purdham et al., 2004; Schulze and Kratzsch, 2005; Karmazyn et al., 2007). 
Furthermore, localised depots of epicardial or perivascular fat might play a significant 
physiological or pathological role (Cheng et al., 2008; Knudson et al., 2008; 
Sweeney, 2010). The physiological response of cardiomyocytes to leptin is a 
negative inotropic function mediated by endogenously produced nitric oxide 
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(Karmazyn et al., 2008). Leptin induces cardiomyocyte hypertrophy and collagen 
synthesis through stimulation of MAPkinase and RhoA/Rho kinase pathways, it 
protects cardiomyocytes from apoptosis induced by chronic ischaemia and 
modulates the fatty acid metabolism in the heart, resulting in an increased rate of 
fatty acid oxidation and thereby increased myocardial oxygen consumption (Atkinson 
et al., 2002; Rajapurohitam et al., 2003; Sharma and McNeill, 2005; Karmazyn et al., 
2007, 2008; Schram et al., 2010; Sweeney, 2010). The latter might contribute to 
decreased cardiac efficiency in cardiac diseases. In heart failure, leptin is involved in 
the neurohormonal activation, due to its central sympathoexcitatory effects and is 
associated with high levels of catecholamines and pro-inflammatory cytokines 
(Haynes et al., 1997a). Furthermore, the leptin induced increased metabolic rate 
results in a progressive catabolic syndrome, and high leptin blood levels have been 
shown to be associated with unfavourable outcomes in human patients (Toth et al., 
1997; Schulze and Kratzsch, 2005). However, controversial observations exist and in 
mice with leptin receptor deficiency, activation of leptin pathways have been reported 
to decrease cardiac hypertrophy, apoptosis and inflammation (McGaffin et al., 2010).  
2.6 Cardiac inflammation and remodelling in the dog 
Progressive cardiac remodelling is known to be associated with concentric or 
eccentric hypertrophy of the left and/or right ventricle in dogs with acquired and 
congenital cardiac diseases. Myocardial function and the degree of hypertrophy can 
be investigated using echocardiography and thoracic radiography and is used to 
assess the severity and progression of cardiac diseases in dogs (Oyama and 
Thomas, 2002; Van Israel et al., 2002; Hori et al., 2008; Yamane et al., 2008; Martin 
et al., 2009; Lord et al., 2011).  
In canine DVD, volume overload results in eccentric left ventricular hypertrophy 
and atrial dilation and is suspected to be associated with loss of collagen and 
cardiomyocyte degeneration (Zheng et al., 2009; Pat et al., 2010). Normal mitral 
valve leaflets consist of four layers, the atrialis, spongiosa, fibrosa and ventricularis, 
and represent a thin, translucent structure without nodules or thickening (Fox, 2012), 
whereas mitral valve leaflets of DVD patients are diffusely thickened and distorted, 
due to increased ECM deposition in the spongiosa and disruption of the collagen 
layers in the fibrosa (Pomerance and Whitney, 1970; Aupperle and Disatian, 2012; 
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Fox, 2012; Lacerda et al., 2012; Orton et al., 2012). The distorted mitral valve 
leaflets cause impaired mechanical valvular function and thereby mitral regurgitation 
and left sided volume overload. 
In canine DCM, a primary myocardial disease is present associated with 
attenuated wavy fibre cardiomyocyte degeneration and/or fatty-fibrous degeneration, 
this causes eccentric left ventricular hypertrophy (Basso et al., 2004; Tidholm and 
Jonsson, 2005; Lobo et al., 2010).  
Activation of SNS, RAAS and NP during progression of the disease is reported in 
dogs with acquired cardiac diseases, but less is known about the presence and type 
of inflammatory process (Koch et al., 1995; Pedersen et al., 1995; Tidholm et al., 
2001b; Uechi et al., 2002; Sisson, 2004; Marcondes Santos et al., 2006; Fujii et al., 
2007; Oyama, 2009; Ettinger et al., 2012). In canine DVD, inflammation is not 
suspected to play an important pathogenic role (Oyama and Chittur, 2006; Aupperle 
and Disatian, 2012; Orton et al., 2012) and an increase in IL-6 transcription (Oyama 
and Chittur, 2006), but no myocardial inflammatory infiltration was detected in dogs 
with DVD (Aupperle and Disatian, 2012; Fox, 2012). Also, Zois et al. reported 
decreased circulating IL-2, IL-7 and IL-8 levels with increased severity of DVD (Zois 
et al., 2012).  
In human medicine, an inflammatory form of DCM has been reported (Kuhl et al., 
1996; Richardson et al., 1996; Noutsias et al., 2002; Westermann et al., 2011), this 
is also suspected in dogs such as Doberman pinschers with DCM (Gilbert et al., 
1997). However, this has so far not been further investigated, for example by 
studying cytokine expression. In a dog model, cytokine stimulation and ischaemia-
reperfusion injury was shown to upregulate the cardiac IL-8 and ICAM-1 production 
(Kukielka et al., 1993; Kukielka et al., 1995; Oyama and Chittur, 2006). 
There is evidence that the cardiac remodelling observed in dogs with DVD is 
influenced by TGF-β, MMP and TIMP. Down-regulation of TGF-β1 transcription was 
seen in a dog model of mitral regurgitation (Zheng et al., 2009), whereas an increase 
of valvular TGF-β1 and TGF-β3, but not TGF-β2 protein expression was detected in 
dogs with DVD (Aupperle et al., 2008). Furthermore, increased MMP-1, MMP-3, 
TIMP-1, -2 and -3, reduced MMP-2 and variably altered MMP-9 production was 
observed in dogs with DVD and the dog model of mitral regurgitation (Oyama and 
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Chittur, 2006; Aupperle et al., 2009a; Zheng et al., 2009; Ljungvall et al., 2011; 
Obayashi et al., 2011; Aupperle and Disatian, 2012). It is hypothesised that ECM 
remodelling in canine DCM is influenced by upregulation of MMP-9 and/or TIMP-1 
(Gilbert et al., 1997; Oyama and Chittur, 2005).  
Obesity is increasingly recognised in veterinary patients, obese dogs have been 
shown to exhibit increased leptin levels (Ishioka et al., 2002; German et al., 2010) 
and a recent study suggested an association of obesity with ventricular hypertrophy 
and cardiac dysfunction in dogs (Mehlman et al., 2013). However, the role of leptin in 
development and progression of canine cardiac disease and CHF has so far not 
been investigated. Congenital cardiac diseases that cause pressure overload 
present with concentric hypertrophy (Oyama and Thomas, 2002), but studies 
investigating the presence of inflammation or cardiac remodelling in these patients 
have so far not been undertaken.  
2.7 Effect of systemic, non-cardiovascular diseases on 
cardiac inflammation and remodelling 
Systemic diseases are known to result in cardiac damage and impaired cardiac 
function in humans and dogs (Parker et al., 1984; Nelson and Thompson, 2006; 
Merx and Weber, 2007; Flynn et al., 2010; Serra et al., 2010; Langhorn et al., 2013). 
In dogs, an association of cardiac function and outcome is suspected (Nelson and 
Thompson, 2006; Bulmer, 2011). It has been shown that circulating endotoxins, a 
systemic inflammatory response with increased circulating catecholamines and 
cytokine levels and the RAAS trigger myocardial inflammation and cause 
cardiomyocyte damage (Chen et al., 2008; Sciarretta et al., 2009; Flynn et al., 2010; 
Scruggs et al., 2010). The innate immune system and resultant inflammatory 
response can be activated by pathogens, i.e. bacteria, but also by tissue destruction 
(Kaczorowski et al., 2009; Cohen, 2010; Bulmer, 2011). Especially Toll-like receptors 
promote the transcription of numerous cytokines via the NF-κB pathway, play a 
central role in myocardial dysfunction in sepsis and are involved in cardiac 
remodelling (Cuenca et al., 2006; Kaczorowski et al., 2009; Cohen, 2010; Bulmer, 
2011). As reported above, it has been shown in animal models that cardiomyocyte 
damage results in cytokine, chemokine and adhesion molecule expression which 
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induces leukocytes recruitment and cardiac inflammation as well as ECM 
degradation (Dobaczewski et al., 2010). Despite a potential marked effect of 
systemic diseases on cardiac function and remodelling and, therefore, morbidity and 
mortality, studies investigating the effect of systemic diseases on the heart in 
animals are sparse (Nelson and Thompson, 2006; Serra et al., 2010; Bulmer, 2011; 
Langhorn et al., 2013). Several systemic diseases in dogs have been shown to be 
associated with increased circulating cardiac troponin I levels, suggesting myocardial 
cell damage (Serra et al., 2010; Langhorn et al., 2013). Nelson and Thompson 
reported a reduced systolic function in dogs with severe systemic illness, such as 
sepsis and cancer, and 75% of these dogs died (Nelson and Thompson, 2006). In 
contrast, dogs that had been discharged showed reversible myocardial depression 
and improved myocardial function at revisit investigations (Nelson and Thompson, 
2006; Dickinson et al., 2007). In people with septic shock, increased ventricular 
volumes and reduced ejection fraction resolved in those patients that survived 
(Parker et al., 1984).  
In human patients with malignant neoplastic diseases and metastases, activation 
of the inflammatory system contributes to clinical signs, progression of disease and 
cardiac cachexia (Seruga et al., 2008). In dogs with lymphoma, increased blood 
levels of markers for remodelling, such as MMP-9, reduced TGF-β1 and increased 
TNF-α levels were detected; these returned to normal in cases of tumour remission 
(Hofer et al., 2011; Aresu et al., 2012). However, the potential effect on cardiac 
function was not investigated in these studies.  
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3 AIMS OF THE STUDY 
The aims of the current study were 
I to investigate the role of inflammation and ECM remodelling in the heart of 
dogs with cardiac diseases and systemic diseases by 
a. Investigating quantitative pro- and anti-inflammatory cytokine and GDF-15 
transcription in the blood and myocardium as markers for cardiac 
inflammation; 
b. Investigating quantitative MMP, TIMP and lox mRNA expression in the 
blood and myocardium as markers for ECM remodelling in the heart; 
c. Investigating potential quantitative differences in inflammatory and ECM 
remodelling processes in different cardiac regions; 
d. Investigating the constitutive cytokine, GDF-15, MMP, TIMP and lox 
transcription in the blood and myocardium of healthy control dogs. 
 
II  to investigate the role of leptin in dogs with cardiac diseases by 
a. Investigating quantitative leptin transcription in blood and myocardium of 
dogs with cardiac and systemic diseases; 
b. Investigating regional differences in leptin transcription in the myocardium 
of dogs with cardiac and systemic diseases. 
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4 MATERIAL AND METHODS 
Dogs with cardiac diseases (see 4.1, Table 1), systemic diseases (see 4.2, Table 
2) and healthy control dogs (see 4.3, Table 3) were included in the PhD project. 
Tables 1, 2 and 3 provide the information on the dogs and the studies of the PhD 
project to which they contributed. 
4.1 Dogs with cardiac diseases (18 dogs)  
All dogs with cardiac diseases were patients presented to the Small Animal 
Teaching Hospital, University of Liverpool, apart from two dogs that had been 
investigated and diagnosed by a cardiologist [Simon Swift, MA, VetMB, CertSAC, 
DipECVIM-CA (Cardiology)] in another practice and had been referred. The most 
frequent breed in this group were Boxer dogs (n=5), followed by Labradors and 
Doberman (n=3 each; Table 1). A physical examination was performed and complete 
blood count (CBC), blood biochemistry, blood pressure measurement, 
electrocardiography (ECG), echocardiography and thoracic radiographs were 
obtained in all dogs. Thoracic radiographs were taken, if the dogs were stable 
enough for sedation and positioning. A Holter monitor (Lifecard CF, Spacelabs 
Healthcare Ltd, Hertford, UK) was applied to confirm the diagnosis and significance 
of arrhythmias. Dogs with various cardiac diseases and without clinical evidence of 
systemic disease were included in this group. Congestive heart failure was 
confirmed by physical examination, echocardiography and/or thoracic radiographs. 
The Canine Heart Failure International Expert Forum (CHIEF) heart failure 
classification scheme was applied (Strickland, 2008; Table 4). Two dogs were in 
heart failure class B, 11 dogs in heart failure class C3 and five dogs in heart failure 
class D. Five dogs had congenital and 13 dogs acquired cardiac diseases. The most 
frequent acquired cardiac diseases were DCM (n=5) and DVD (n=4). Three dogs 
with DCM (dogs 10, 11, 13) and one dog with DVD (dog 17) had atrial fibrillation. 
Dogs that were found to be in CHF were stabilised with heart failure medication, 
including furosemide, nitroglycerine, pimobendan, benazepril and spironolactone. 
The treatment of the dogs was individualised and subject to the discretion of the 
attending cardiologist, following the recommendations for the treatment of dogs with 
acute CHF and according to the individual response to treatment. 
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4.2 Dogs with systemic diseases (10 dogs) 
All dogs in this group had been patients of the Small Animal Teaching Hospital, 
University of Liverpool. A physical examination was performed, and CBC and blood 
biochemistry were obtained (Table 2). Further investigations were undertaken to obtain 
a diagnosis, including combinations of urinalysis, ultrasonography, radiography, 
computed tomography, magnetic resonance imaging, fine needle aspirates and/or 
biopsies when indicated. Only dogs with systemic diseases that did not involve the heart 
were included in the study. Among these, lymphomas (n=4) and brain tumours (n=2) 
were most frequent. 
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4.3 Healthy control dogs (16 dogs) 
Eight dogs of this group were recruited from the cohort of healthy dogs that were 
screened for DCM at the Small Animal Teaching Hospital, University of Liverpool as 
part of LUPA (www.eurolupa.org) and eight dogs were control dogs from a 
pharmaceutic company (Pfizer; Table 3). Dogs screened for DCM underwent physical 
examination, and CBC, blood biochemistry, blood pressure measurement, ECG and 
echocardiography were obtained. In four Great Danes, the thyroid function (T4, TSH) 
was investigated. Animals from the pharmaceutic company were clinically healthy. The 
data and myocardial samples had been collected and were provided by the company.  
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Table 4: CHIEF heart failure classification (Strickland, 2008). 
Class Definition 
A Risk of heart disease, but currently no identifiable structural disorder of the heart 
B Structural heart disease documented but never developed clinical signs of heart failure 
C1 Past or current 
clinical signs of heart 
failure associated 
with structural heart 
disease 
Past no clinical signs of heart failure (stabilized/past 
heart failure) 
C2 Current mild-moderate heart failure 
C3 Current severe heart failure 
D End-stage cardiac disease with clinical signs of heart failure refractory to standard therapy 
 
4 METHODS 
The PhD project comprised four studies. Study I investigated circulating markers 
of inflammation and ECM remodelling in blood samples of dogs with cardiac 
diseases, studies II and III analysed myocardial markers of inflammation and ECM 
remodelling in dogs with cardiac and systemic diseases and study IV investigated 
circulating and myocardial leptin mRNA levels in dogs with cardiac diseases. For all 
studies owner consent was obtained and dogs were assigned arbitrary numbers as 
identifiers in order to maintain confidentiality. 
4.4 Circulating markers of inflammation and ECM 
remodelling 
As part of the general investigation, EDTA blood samples for CBC analysis were 
collected from dogs shown in tables 1 and 3 prior to administration of any 
medication. From these blood samples, 0.3 mL was immediately taken and frozen at 
-20°C for 8-24 h within 10 min after sampling, then stored at -80°C until further 
processing. 
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4.5 Myocardial markers of inflammation and ECM 
remodelling 
Myocardial samples were collected from carcasses of dogs euthanased upon 
owner’s request, due to end-stage systemic or cardiac diseases and poor prognosis, 
or in the case of one dog with recurrent ventricular tachycardia that had developed 
ventricular fibrillation (dog 6), after spontaneous death (Tables 1 and 2). The hearts 
were removed within one hour after death and grossly examined for any pathological 
changes. Myocardial samples of approximately 3 mm3 were collected from the 
interventricular septum (IVS), right atrium and ventricle (RA, RV) and left atrium and 
ventricle (LA, LV) for RNA extraction and stored in RNAlater (Life Technologies Ltd, 
Paisley, UK) at -20°C until use. Hearts were subsequently fixed in 10% formalin and 
samples from the same sites as those for RNA extraction were prepared and 
routinely paraffin wax embedded for the histological examination (see 4.7).  
The myocardial samples of control dogs were donated from a pharmaceutical 
company (Pfizer; Table 3). These dogs had been euthanased and grossly examined 
on site at the pharmaceutical company. Samples from the LA, RA, LV and RV had 
been collected and immersed in RNAlater (Life Technologies Ltd) immediately after 
death.  
4.6 PCR analysis of blood and myocardium (I-IV) 
4.6.1 Primer design (I-IV) 
Primers for cytokines, growth differentiation factor-15 (GDF-15), leptin and lysyl 
oxidase (lox) were designed using the Primer Express software (Life Technologies 
Ltd). They were selected to span predicted exon boundaries, where possible (Table 
5a). BLAST searches were performed to confirm the gene specificity. Target and 
reference gene primers were synthesised by Eurogentec (Southampton, UK). For 
the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
matrix metalloproteinase (MMP)-1, -2, -3, -9 and tissue inhibitor of metalloproteinase 
(TIMP)-1-4 previously reported published sequences were used (Table 5b) 
(Clements et al., 2006; Garvican et al., 2008; Clements et al., 2009). Primers were 
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validated by standard curve of eight serial dilutions and primer efficiencies were 
between 96% and 120% (Table 5a, b).  
Table 5a: Primer sequences, position, accession number of the National Center for 
Biotechnology Information and efficiency used for quantitative PCR (Studies I, II, IV).  
Primer  Sequence (5’ – 3’) Position Accession number 
Efficiency 
% 
IL-1 forward ATGAGGGCATCCAGTTGCA 154-172 DQ923807 114 reverse CACGAAATGCCTCAGACTCTTG 216-194 
IL-2 forward AGATGGAGCAATTACTGCTGG 122-142 AM238655.1 114 reverse ATTCTGTGGCCTTCTTGGGCGTGT 241-218 
IL-4 forward ACATCCTCACAGCGAGAAACG 182-202 AF187322 117 reverse GCAGTGAAGACGTCCTTGACAGT 242-220 
IL-6 forward GGCTACTGCTTTCCCTACCC 51-70 AF275796 96 reverse TTTTCTGCCAGTGCCTCTTT 248-229 
IL-8 forward TTGCCTTGGTCTCTTCTTTATTCC 663-687 NM_001003200 97 reverse TTCTGTGAGGTAGGATGCTTGCT 729-707 
IL-10 forward CCTGGGTTGCCAAGCCCTGTC 234-254 EU426968.1 98 reverse ATGCGCTCTTCACCTGCTCC 439-420 
TNF-α forward TCTCGAACCCCAAGTGACAAG 241-261 X94932.1 111 reverse GGAGCTGCCCCTCAGCTT 307-290 
IFN-γ forward 
GAAAAGGAGTCAGAATCTGTTTC
GA 561-585 NM_001003174.1 115 reverse TGCAGGCAGGATGACCATTA 623-604 
TGF-β1 forward CACCCGCGTGCTAATGGT 381-400 NM_001003309.1 107 reverse GCGGACTTTTCTTGACTTTCTCA 442-420 
TGF-β2 forward GACCCCACATCTCCTGCTAA 915-934 XM_545713.3 100 reverse CACCCAAGATCCCTCTTGAA 1079-1069 
TGF-β3 forward GGCTGGCGGAGCACAAT 401-417 DQ310186.1 99 reverse AAACCTTGGAGGTGATTCCTTTG 457-435 
Leptin forward ACCGTATGGGTGTCCTTTATCCT 604-621 NM_001003070.1 120 reverse AGAGTGGCTCTGTGGTGTGAGA 666-645 
Lox forward TGCTTGGAGGACACAGAATG 2165-2184 XM_543244.3 99 reverse ACAGGTAGTCTCCAGGGGGT 2324-2305 
GDF-15 
forward ACTCCAGTACCGACGTGTCC 140-159 XM_54193
8.1 96 reverse TCGCAGCTTTGGAGTGAGTA 288-269 
GDF: growth differentiation factor, IFN: interferon, IL: interleukin, Lox: lysyl oxidase, TGF: 
transforming growth factor, TNF: tumour necrosis factor. 
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Table 5b: Primer sequences, their references and efficiency used for quantitative 
PCR (Studies I-IV). 
Primer  Sequence (5’ – 3’) Reference Efficiency % 
GAPDH forward CTGGGGCTCACTTGAAAGG Clements et al 2006 98-100 reverse CAAACATGGGGGCATCAG 
MMP-1 
forward GGTGAAGGAAGGTCAAGTTCTGAT 
Garvican et al 2008 95 reverse AGTCTTCTACTTTGGAAAAGAGCTTCTCT 
MMP-2 forward ACCTGCAAGGCAGTGGTC Clements et al 2009 99 reverse TCCAAATTTCACGCTTTTCA 
MMP-3 forward TCTTGCCGGTCAGCTTCATATAT Garvican et al 2008 96 reverse CCTATGGAAGGTGACTCCATGTG 
MMP-9 forward CACGCATGACATCTTCCAGT Clements et al 2009 92 reverse CGAGAATTCACACGCCAGTA 
MMP-13 forward CCGCGACCTTATCTTCATCT Clements et al 2006 103 reverse AACCTTCCAGAATGTCATAACCA 
TIMP-1 forward TGCATCCTGCTGTTGCTG Clements et al 2006 97 reverse AACTTGGCCCTGATGACG 
TIMP-2 forward ATGGGCTGTGAGTGCAAGAT Clements et al 2006 99.5 reverse CACTCATCCGGAGACGAGAT 
TIMP-3 forward CCTACTTCCCCATTAGCCAGTCT Garvican et al 2008 98 reverse ACAGGGTTTTCTCTGGTTGGTTT 
TIMP-4 
forward GCAGAGAGAAAGTCTGAATCATCA 
Clements et al 2006 97 
reverse GGCACTGTATAGCAGGTGGTAA 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase, MMP: matrix metalloproteinase, 
TIMP: tissue inhibitor of matrix metalloproteinase. 
4.6.2 RNA isolation 
4.6.2.1 RNA isolation from blood samples (I, IV) 
A commercially available kit (RiboPure blood kit, Life Technologies Ltd) was 
used, following the manufacturer’s protocol. To prepare the solutions for RNA 
isolation, 56 mL 100% ethanol was added to Wash Solution 2/3 and the Elution 
Solution was heated to 75ºC in an RNase-free tube. 
For RNA isolation, 800 µL Lysis Solution and 50 µL Sodium Acetate Solution was 
added to 0.3 mL defrosting blood which was then thoroughly mixed by vortexing until 
the solution was homogenous. 500 µL of Acid-Phenol-Chloroform, taken from 
beneath the overlying layer of aqueous buffer was added to the cell lysate. The fluid 
was thoroughly mixed for 30 s by vortexing. The mixture was stored for 5 min at 
room temperature (RT), followed by centrifugation for 1 min at 10,000 x g at RT to 
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separate the aqueous and organic phases. The aqueous (upper) phase was 
transferred into a new 2 mL collection tube, the lower phase was discarded. 600 µL 
(½ of the recovered volume) of 100% ethanol was added and the fluid briefly and 
thoroughly mixed. 700 µL of the sample was transferred to a filter cartridge assembly 
and centrifuged for 5-10 s at 10,000 x g to pass the liquid through the filter. The flow 
through was discarded and another 700 µL were loaded onto the same filter, 
centrifuged for 5-10 s at 10,000 x g and the flow-through was again discarded. This 
step was repeated with the remaining sample. 700 µL Wash Solution 1 was added 
onto the filter, the tube was centrifuged for 5-10 s at 10,000 x g and the flow through 
was discarded. 700 µL Wash Solution 2/3 was added onto the filter, the tube was 
centrifuged for 5-10 s at 10,000 x g and the flow-through was discarded. This step 
was repeated. The tube was then centrifuged for 1 min to remove residual fluid from 
the filter. The filter was transferred into a collection tube and 40 µL preheated Elution 
Solution was added to the centre of the filter. The solution was incubated at RT for 
20 s and the tube centrifuged for 30 s at 13,000 x g. Another 40 µL of preheated 
Elution Solution was added and the tube centrifuged for 1 min at 13,000 x g to collect 
the RNA into the same tube. The eluted RNA (total volume of 80 µL) was stored at -
80ºC until further use.  
For DNase treatment, 4 µL 20 X DNase Buffer and 1 µL DNase was added to the 
eluted RNA (80 µL) and the sample gently and thoroughly mixed, followed by 
incubation for 30 min at 37ºC. 16 µL DNase Inactivation Reagent was added and the 
sample briefly vortexed to thoroughly mix DNase Inactivation reagent and RNA. 
Whilst incubating at RT for 2 min, the sample was briefly vortexed once or twice, 
then centrifuged for 1 min at maximum speed to pellet the DNase Inactivation 
reagent. The RNA was transferred into a new RNase-free tube. The RNA content of 
each sample was measured using a spectrophotometer (ND-1000, Nanodrop 
Technologies, Thermo Scientific, Wilmington, USA) and the samples were stored at -
80ºC until further use. 
4.6.2.2 RNA isolation from myocardial samples (II-IV) 
A commercially available kit (RNA minikit, Qiagen Ltd, Manchester, UK) was used 
and the manufacturer’s protocol was followed. To prepare the solutions for RNA 
isolation, 10 μL β-mercaptoethanol was added to 1 mL RLT buffer, and 4 volumes of 
ethanol (96-100%) was added to buffer RPE prior to first use. Myocardial samples 
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frozen in RNAlater were removed from the RNAlater, placed in a 1.5 mL Eppendorf 
tube and snap frozen in liquid nitrogen. The frozen tissue was placed into a new 1.5 
mL Eppendorf tube with 300 µL RLT buffer and was disrupted with a pestle. 590 µL 
RNase free water and 10 µL Proteinase K (Qiagen Ltd) were added, and the sample 
thoroughly mixed and incubated for 10 min at 55ºC. The tube was centrifuged for 3 
min at 10,000 x g at RT and the supernatant transferred into a new Eppendorf tube. 
The equivalent of ½ of the volume (450 µL) of 70% ethanol was added and the fluid 
immediately mixed by pipetting. 700 µL of the fluid was transferred to an RNeasy 
spin column that was placed in a 2 mL collection tube. The lid was closed and the 
tube was centrifuged for 15 s at 10,000 x g. The flow through was discharged and 
the step repeated with the remainder of the sample. 350 µL RW1 buffer was added 
and the fluid centrifuged for 15 s at 10,000 x g. The flow through was discarded. 10 
µL DNase 1 stock solution was added to 70 µL RDD and gently mixed. This mixture 
was transferred to the spin column and incubated for 15 min at RT. 350 µL RW1 
buffer was added to the spin column. The tube was centrifuged for 15 s at 10,000 x g 
and the flow through discarded. 500 µL RPE was added, the tube centrifuged for 15 
s at 10,000 x g and the flow through discarded. 500 µL RPE was added and the tube 
centrifuged for 2 min at 10,000 x g. The RNeasy spin column was removed and 
placed into a new 2 mL collection tube, then centrifuged at maximum speed for 1 
min. The old collection tube with the flow through was discarded. The RNeasy spin 
column was placed in a new 1.5 mL collection tube, 30 µL RNase free water was 
added and the tube centrifuged for 1 min at 10,000 x g. Another 40 µL RNase free 
water was added and the tube centrifuged for 1 min. The RNA content was 
measured and the sample (total volume of 70 µL) stored at - 80ºC until further use. 
4.6.3 Synthesis of cDNA (I-IV) 
200 ng and 500 ng of total RNA isolated from blood and myocardium, 
respectively, was used to synthesise cDNA, using Moloney murine leukemia virus 
reverse transcriptase (Promega, Southampton, UK) and primed with random 
hexamer oligonucleotides (Promega) in a 25 μl reaction. The RNA was incubated 
with 0.5 µg random hexamers and RNase free water (to a volume of 13 µL) at 70ºC 
for 5 min. This was added to the Mastermix consisting of 5 µL 5X reaction buffer, 
nucleotides (dATP, dCTP, dGTP, dTTP, 0.5 mM each), RNase inhibitor (1 U/µL) and 
reverse transcriptase (2.5 U/µL). The mixture was incubated at 25ºC for 5 min, which 
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was followed by incubation at 37ºC for 60 min. Inactivation of the reverse 
transcriptase was achieved by incubation at 93ºC for 5 min. cDNA was stored at -
80°C until use in the quantitative PCR. 
4.6.3 Quantitative PCR (I-IV) 
Aliquots (1 μL) of the cDNA were amplified in duplicates by PCR on an ABI 7700 
Sequence Detector (Life Technologies Ltd) using the SYBR Green PCR mastermix 
(Life Technologies Ltd). Each assay well had a 20 μL reaction volume consisting of 
10 μL 2X SYBR Green PCR Mastermix, 0.4 μL each of 10 μM forward and reverse 
primers and 1 μL of sample cDNA (templates) or water (negative controls). The 
amplification was performed according to a standard protocol with 2 min incubation 
at 50°C, and initial denaturation for 10 min at 90°C, followed by 40 cycles of 
denaturation at 95°C for 15 s and annealing at 60°C for 1 min. The PCR was 
followed by a dissociation programme, represented by incubation for 1 min at 95°C 
and subsequent 41 cycles during which the temperature was increased for 1ºC at 
each cycle, starting at 55°C and ending at 95°C. All PCR reactions exhibited one 
well-defined melting-curve peak. Real-time data were analysed by the Sequence 
Detection Systems software, version 2.2.1 (Life Technologies Ltd). Relative 
expression levels were normalised to GAPDH and calculated using the 2-ΔΔCt method 
(Livak and Schmittgen, 2001). 
4.7 Histological examination (II-IV) 
For the histological examination, two consecutive 3-5 μm thick sections were 
prepared from the formalin-fixed, paraffin-embedded myocardial samples of all 
diseased dogs. The first section was stained with haematoxylin-eosin (HE) for the 
assessment of any pathological changes. To the second section the Masson 
trichrome stain was applied for the evaluation of the amount and distribution of 
collagen in the myocardium. The histological examination was undertaken by Dr. 
Udo Hetzel (Dr.rer.nat., Dr.med.vet., FTA Pathologie, MRCVS), Docent in Veterinary 
Ultrastructural Pathology, University of Helsinki who recorded all histopathological 
changes. The most relevant findings [i.e. lipomatosis cordis, cardiac (interstitial, 
subendocardial or subepicardial) fibrosis, leukocyte infiltration, muscular hypertrophy 
of small arteries, cardiomyocyte necrosis] were scored semiquantitatively. Healthy 
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control hearts were used as reference, and the observed changes in the hearts of 
diseased dogs graded as mild (+), moderate (++) or severe (+++). 
4.8 Statistical analysis 
Real time PCR data were entered into Excel spreadsheets (Microsoft 
Corporation, Reading, Berkshire, UK) and the statistical analysis was performed, 
using Minitab 15 or 16 (Minitab Inc, State College, PA, USA). Basic descriptive 
statistics (mean, median, variance, standard deviation, interquartile range, 
confidence interval) were obtained. Following these, a number of variables were 
transformed to improve normality and model assumptions. IL-1β, IL-4 IL-6, IL-10, 
TNF-α, TGF-β2, TGF-β3, GDF-15, MMP-2, MMP-9, TIMP-1, -2, -3, -4, and leptin 
transcription values were log transformed and the inverse square root was applied to 
IL-2, IL-8, TGF-β1, MMP-1, -3, and MMP-13, whereas the square root was used for 
lox and the inverse expression for IFN-γ. 
The age and body condition score (BCS) of the dogs from which blood samples 
were examined (Studies I and IV) were not normally distributed and a Mann Whitney 
U test was used to compare these parameters in dogs with and without cardiac 
disease or CHF. All other parameters were normally distributed or normalised and 
the one-way ANOVA test was applied. The weight of the dogs, and the cytokine, 
growth factor, MMP and TIMP mRNA levels of control and CHF dogs in study I were 
compared using a one-way ANOVA test. In study IV, the weight between groups and 
the differences in leptin RNA levels between sex, dogs with and without cardiac 
disease or CHF, heart failure stage, different regions of the heart and different 
cardiac disease groups were compared using a one-way ANOVA test. The relation 
between leptin and body weight and BCS was examined with scatterplots and then 
tested with the Pearson correlation test. 
In study II and III the amount of cytokine and GDF-15 (Study II) and of MMP, 
TIMP and lox (Study III) mRNA in myocardial samples from various heart regions 
were compared in control dogs, dogs with systemic diseases and dogs with cardiac 
diseases. To investigate the degree of myocardial MMP, TIMP, and lox mRNA 
expression of dogs with CHF and DCM, the data collected from the myocardium of 
these dogs were grouped and compared with those from dogs with cardiac diseases 
other than CHF and DCM, control dogs and dogs with systemic diseases. Data 
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generated from atria and ventricular samples of dogs with atrial fibrillation were 
compared with those of dogs with cardiac diseases without atrial fibrillation and dogs 
with systemic diseases. Results are displayed as range and median or mean and 
standard deviation as appropriate. 
Cluster analysis was performed with normalised and non-normalised data to 
explore the relation between cytokines, MMP, TIMP in blood samples of dogs with 
CHF (Study I), between cytokines and GDF-15 (Study II) and between MMP, TIMP, 
lox (Study III) in dogs with cardiac diseases, using the correlation matrix and a Ward 
linkage dendrogram. Individual correlations were examined with the Pearson 
correlation test. A trend for statistical significance was defined as p<0.1, statistical 
significance was defined as p<0.05. 
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5 RESULTS 
The results presented here are a summary of the detailed results that are 
presented in the four manuscripts that are included into the thesis. 
5.1 Dogs included in studies I–IV 
In study I, blood samples of 8 dogs with cardiac diseases and 8 healthy control 
dogs were compared. Study II was conducted on myocardial tissue of 7 dogs with 
systemic diseases, 7 dogs with cardiac diseases and 8 healthy control dogs, and 
study III comprised myocardial samples of 6 dogs with systemic diseases, 9 dogs 
with cardiac diseases and 8 control dogs. Study IV was undertaken on blood 
samples of 8 dogs with cardiac diseases and 8 healthy control dogs, and on 
myocardial samples of each 10 dogs with cardiac and systemic diseases. In this 
study, the dogs with systemic diseases served as control, since samples of healthy 
control dogs were not available. Information on the dogs included in studies I-IV is 
presented in tables 1, 2 and 3. 
5.2 Pathological changes in the heart of dogs with cardiac 
and systemic diseases (II-IV) 
A gross and histopathological examination was performed on all dogs with 
cardiac and systemic diseases to confirm or exclude the diagnosis of cardiac 
disease, respectively, and to investigate the myocardium for any pathological 
changes in dogs with systemic diseases (Studies II-IV). The gross pathological 
evaluation confirmed the clinical diagnosis in all dogs with heart disease. The 
histological examination revealed that dogs with DCM had features consistent with 
the fibrous fatty type described in the literature (Tidholm and Jonsson, 2005). Dogs 
with other cardiac diseases exhibited only minor changes, except for dog 18, which 
had suffered from pyogranulomatous epicarditis and myocarditis. The gross 
examination did not identify any significant changes in dogs with systemic diseases. 
However, three dogs with lymphoma (dogs 22 - 24) showed neoplastic infiltrates in 
the myocardium and were therefore excluded from studies II and III. The histological 
examination of all other dogs with systemic diseases did not yield any significant 
findings. 
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5.3 Role of inflammation in dogs with cardiac and systemic 
diseases (I, II) 
To investigate the role of inflammation in dogs with cardiac and systemic 
diseases, blood and myocardial samples of dogs with cardiac and systemic diseases 
were investigated for the transcription of pro-inflammatory cytokines IL-1, IL-2, IL-6, 
IL-8, TNF-α, IFN-γ and anti-inflammatory and profibrotic cytokines IL-4, IL-10, TGF-
β1, TGF-β2 and TGF-β3. Based on the transcription of IL-4, IL-10, IFN-γ and TGF-β, 
a potential predominance of a T helper subpopulation would be identified. The 
results were compared with the mRNA expression in blood and myocardial samples 
of control dogs.  
5.3.1 Circulating markers of inflammation in dogs with cardiac 
diseases (I) 
In most blood samples, constitutive transcription of IL-1, IL-2, IL-6, IL-8, IL-10, 
TNF-α, IFN-γ, TGF-β1 and TGF-β3 was identified, whereas IL-4 and TGF-β2 mRNA 
was not detected. In comparison to control dogs, dogs with cardiac diseases 
exhibited a significant increase in the transcription of IL-1 (p=0.015) and IL-2 
(p=0.043), whereas the TNF-α (p<0.001), TGF-β1 (p=0.098) and TGF-β3 (p=0.006) 
mRNA expression was reduced (Fig. 2). No difference was detected for IL-8 
(p=0.146), IL-6 (p=0.52), IL-10 (p=0.94) and IFN-γ (p=0.47). 
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Figure 2. Study I; relative TNF-α, TGF-β1 and TGF-β3 mRNA expression in the 
blood of dogs with cardiac disease (CD; n=8) and of healthy control dogs (Control; 
n=8). For all three cytokines transcriptions were higher in control dogs. Intervalplot 
showing 95% confidence interval. TNF: tumour necrosis factor, TGF: transforming 
growth factor. 
 
5.3.2 Myocardial markers of inflammation in dogs with cardiac and 
systemic diseases (II) 
In control dogs, only TNF-α, TGF-β1, and TGF-β3 were transcribed in the 
myocardium, with higher levels in the male dogs (p<0.001; Fig. 3). These 
transcription levels were higher than in male dogs (p<0.005) and lower than in 
female dogs (p<0.016) with cardiac and systemic diseases, comparing the 
respective sexes. 
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Figure 3. Study II; relative TNF-α and TGF-β3 mRNA expression in the myocardium 
of male (M; n=8) and female (F; n=8) healthy control dogs. Transcription levels of 
both cytokines were significantly higher in male dogs. Intervalplot showing 95% 
confidence interval. TNF: tumour necrosis factor, TGF: transforming growth factor. 
 
 
All markers of inflammation were found to be transcribed in the myocardium of 
dogs with cardiac and systemic diseases, with significantly higher transcription levels 
for IL-1 (p=0.001), IL-6 (p=0.007), IL-8 (p<0.001), IL-10 (p=0.001), TNF-α (p=0.004) 
and IFN-γ (p=0.008) in dogs with cardiac than dogs with systemic diseases (Fig. 4). 
The expression of IL-2 (p=0.008) and IFN-γ (p=0.042) was significantly higher in 
both atria and of IL-1 (p=0.012) and TGF-β1 (p=0.048) in the right atrium, compared 
with findings for the ventricles of dogs with cardiac diseases (Fig. 5). 
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Figure 4. Study II, relative IL-1, IL-6 and IL-10 mRNA expression in the myocardium 
of dogs with cardiac disease (CD; n=7) and systemic diseases (SD; n=7). For all 
three cytokines, transcription levels were significantly higher in dogs with cardiac 
diseases. Intervalplot showing 95% confidence interval for the mean. IL: interleukin.  
 
Figure 5. Study II, relative IL-1, IL-2 and IFN-γ mRNA expression in atrial (A) and 
ventricular (V) samples of dogs with cardiac disease (n=7). For all three cytokines, 
transcription levels were significantly higher in the atria. Results for IL-2 and IFN-γ 
were inversed for normalization. Intervalplot showing 95% confidence interval for the 
mean. IL: interleukin, IFN: interferon.  
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A comparison of the cytokine expression in atria and ventricles of dogs with 
cardiac and systemic diseases showed significantly higher IL-1 (p=0.031), IL-8 
(p<0.001), TNF-α (p=0.048), TGF-β1 (p=0.03) and TGF-β3 (p=0.022) mRNA levels 
in the atria and significantly higher IL-8 (p=0.033), IL-10 (p=0.002), TNF-α (p=0.044) 
and IFN-γ (p=0.004) mRNA levels in the ventricles of dogs with cardiac diseases. 
5.4 Role of ECM remodelling in dogs with cardiac and 
systemic diseases (I, III) 
The presence, type and degree of ECM remodelling was investigated by the 
quantitative assessment of MMP-1, -2, -3, -9 and -13 and TIMP-1, -2, -3 and -4 
transcription in dogs with cardiac and systemic diseases in comparison to control 
dogs. 
5.4.1 Circulating markers of ECM remodelling in dogs with cardiac 
diseases (I) 
MMP-1, -3, -9 and TIMP-1, -2, and -3 were constitutively transcribed in the blood 
of all control dogs, whereas MMP-2 and TIMP-4 mRNA mRNA was not detected. 
Dogs with cardiac disease had significantly higher MMP-1 (p=0.031), MMP-3 
(p=0.061) and TIMP-3 (p=0.012) and lower TIMP-1 (p=0.015) and TIMP-2 (p=0.011) 
mRNA blood concentrations than control dogs (Fig. 6). No difference was observed 
for MMP-9 (p=0.65).  
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Figure 6. Study I, relative MMP-1, MMP-3, TIMP-1 and TIMP-2 mRNA expression in 
the blood of dogs with cardiac disease (CD; n=8) and healthy control dogs (Control, 
n=8). MMP-1 and MMP-3 were increased in dogs with cardiac disease, whereas 
TIMP-1 and TIMP-2 were higher in control dogs. Intervalplot showing 95% 
confidence interval. MMP: matrix metalloproteinase, TIMP: tissue inhibitor of matrix 
metalloproteinase. 
 
 
5.4.2 Myocardial markers of ECM remodelling in dogs with cardiac 
and systemic diseases (III) 
In the control dogs, only mRNA for TIMP-3 and TIMP-4 was detected, and at 
significantly higher concentrations in male than in female dogs (p<0.001). In 
myocardium of dogs with cardiac and systemic diseases all MMP and TIMP were 
transcribed, and the mean TIMP-3 and TIMP-4 transcription levels were significantly 
higher in diseased than in control dogs (p<0.001). While there were overall no 
significant differences between dogs with cardiac diseases and those with systemic 
diseases, dogs with CHF and DCM showed significantly higher myocardial MMP-2 
(CHF p=0.01; DCM p=0.019) and TIMP-1 (CHF p=0.024; DCM p<0.001) than dogs 
with other cardiac and systemic diseases; dogs with DCM had additionally elevated 
myocardial TIMP-2 (p=0.028) mRNA levels (Fig. 7). 
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Figure 7. Study III, relative MMP-2, TIMP-1, and TIMP-2 mRNA expression in all 
dogs with cardiac diseases (CD; n=9), dogs with dilated cardiomyopathy (DCM; 
n=4), and dogs with systemic diseases (SD; n=6). For all three markers, transcription 
levels were significantly higher in dogs with DCM. Interval plot showing 95% 
confidence interval for the mean. MMP: matrix metalloproteinase, TIMP: tissue 
inhibitor of matrix metalloproteinase.  
 
 
The comparison of cardiac regions in diseased dogs identified significantly higher 
transcription levels for MMP-1 (p=0.002), MMP-2 (p=0.006), TIMP-2 (p=0.014) and 
TIMP-3 (p=0.032) in the atria than the ventricles. Especially dogs with atrial 
fibrillation showed a significantly greater degree of MMP-2 (p=0.024), MMP-13 
(p=0.046) and lox (p=0.005) transcription than dogs with systemic diseases (Fig. 8). 
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Figure 8. Study III, relative MMP-2, MMP-13 and lysyl oxidase (Lox) mRNA 
expression in atrial samples of dogs with atrial fibrillation (AF; n=4) in comparison to 
dogs with systemic diseases (SD; n=6). For all three markers, transcription levels 
were significantly higher in atria of dogs with atrial fibrillation. Intervalplot showing 
95% confidence interval for the mean. MMP: matrix metalloproteinase, Lox: lysyl 
oxidase. 
 
5.5 Role of leptin in dogs with cardiac diseases (IV) 
To investigate the role of leptin in canine cardiac diseases, its transcription in 
blood and myocardium of dogs with cardiac disease was compared with blood 
samples of healthy control dogs and myocardial samples of dogs with systemic 
diseases, respectively. 
5.5.1 Circulating and myocardial leptin transcription in dogs with 
cardiac and systemic diseases (IV) 
Leptin transcription was detected in all blood and myocardial samples 
investigated. Dogs with CHF exhibited significantly higher transcription levels (3.54, 
standard deviation ± 0.76) in the blood than healthy control dogs (2.52 ± 0.73; 
p=0.013). In the myocardium highest mRNA levels were found in dogs with acquired 
cardiac diseases (1.74 ± 0.78) and lowest levels in dogs with congenital cardiac 
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diseases (0.66 ± 0.86), and the levels were significantly higher (p=0.035) and lower 
(p=0.016), respectively, than in dogs with systemic diseases (control group; 1.32 ± 
0.92). Among dogs with cardiac diseases, those with heart failure stage D (1.72 ± 
0.91) showed higher leptin mRNA levels than those in heart failure stage C3 (1.18 ± 
1.24) and B (1.02 ± 0.53; p=0.031). Also, in dogs with cardiac diseases (Table 6) 
transcription levels were higher in atria than in ventricles. Furthermore, in dogs with 
cardiac diseases, female dogs had significantly higher myocardial leptin mRNA 
levels than male dogs (p=0.001). 
 
Table 6. Study IV, relative leptin expression in different cardiac regions of dogs with 
acquired and congenital cardiac diseases, and dogs with systemic diseases. Results 
are displayed as mean with standard deviation. The p-value is the difference 
between cardiac regions for each group. 
 
Cardiac region Acquired cardiac disease (n=7) 
Congenital cardiac 
disease (n=3) 
Systemic diseases 
(controls, n=10) 
Interventricular 
septum 0.96 ± 0.83 0.02 ± 0.67 0.65 ± 0.49 
Left atrium 2.37 ± 0.59 1.45 ± 0.38 1.18 ± 0.85 
Left ventricle 1.36 ± 0.76 0.03 ± 1.14 1.68 ± 1.14 
Right atrium 2.28 ± 0.54 0.88 ± 0.42 0.71 ± 0.52 
Right ventricle 1.73 ± 0.84 0.74 ± 0.56 1.74 ± 0.77 
 p=0.004 p=0.075 p=0.001 
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6 DISCUSSION 
Cardiac remodelling is a complex process and involves an inflammatory system 
and an imbalance of ECM components. To investigate cardiac remodelling in dogs, 
three studies (Studies I, II and III) of the PhD project investigated the transcription of 
markers for inflammation (pro- and anti-inflammatory cytokines) and ECM 
remodelling (MMP and TIMP) and the fourth study investigated the mRNA 
expression of leptin in the blood and myocardium of dogs. For all markers, the 
relative expression was quantified in different groups of dogs, i.e. dogs with cardiac 
diseases, dogs with systemic diseases not involving the heart, and healthy control 
dogs. The latter served to establish the constitutive expression pattern and degree of 
the investigated markers. As expected, transcription levels were generally lowest in 
healthy control dogs and highest in dogs with cardiac diseases. Interestingly, also 
dogs with systemic diseases not involving the heart showed increased myocardial 
transcription of the investigated markers. The results of the PhD study provide 
further details relevant for the pathogenesis of cardiac inflammation and remodelling 
in dogs with cardiac and systemic diseases.  
6.1 Markers of inflammation and ECM remodelling in dogs 
with cardiac diseases 
Activation of the inflammatory system in association with an imbalance of ECM 
remodelling has been reported in human patients with cardiac disease and CHF 
(Bradham et al., 2002a; Anker and von Haehling, 2004; Chen et al., 2008; Graham 
et al., 2008), whereas its role in canine cardiac diseases is not known. In the 
presented work, the expression of inflammatory and ECM markers was studied in 
dogs with cardiac diseases, both in the blood (Study I) and in the myocardium itself 
(Studies II and III). Dogs with cardiac diseases exhibited significantly higher 
circulating IL-1, IL-2, MMP-1, -3 and TIMP-3 mRNA levels than healthy control dogs, 
but significantly reduced TNF-α, TGF-β3, TIMP-1 and TIMP-2 levels, while no 
differences were seen for IL-6, IL-8, IL-10 and IFN-γ (Study I). In contrast, the 
expression of all markers of inflammation and ECM remodelling was significantly 
increased in the myocardium of dogs with cardiac and systemic diseases in 
comparison to controls, and a further increase of the inflammatory markers IL-1, IL-6, 
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IL-8, IL-10, TNF-α, IFN-γ and the ECM remodelling markers MMP-2, TIMP-1 and 
TIMP-2 was observed in dogs with cardiac diseases versus those with systemic 
diseases (Studies II and III). These results confirm those of previous studies that 
suggest that cardiac diseases are associated with an inflammatory state of the 
myocardium and cardiac remodelling (Anker and von Haehling, 2004; Chen et al., 
2008). Cardiac remodelling was reflected by the gross post mortem results and 
clinically by ventricular dilatation or hypertrophy and myocardial dysfunction. The 
lack of inflammatory marker upregulation in the blood alongside the increase of 
inflammatory markers in myocardium suggests primary myocardial activation of the 
inflammatory system and not a myocardial response to circulating inflammatory 
mediators. Furthermore, the histological examination did not reveal substantial 
myocardial inflammatory cell infiltration (Studies II and III), which renders 
cardiomyocytes and cells of the ECM the likely source of the markers (Tyagi et al., 
1993; Kuhl et al., 1996; Li et al., 1999; Frangogiannis, 2008; Souders et al., 2009). 
The stimulation of cytokine, MMP and TIMP expression in cardiac diseases, which 
further stimulates their own and each other’s expression through auto- and paracrine 
loops, might be caused by haemodynamic abnormalities that result in increased 
cardiac stretch and activation of the neurohormonal system (Weber et al., 1994; 
Opie, 2002; Heineke and Molkentin, 2006; Dobaczewski et al., 2010; Frangogiannis, 
2012). IL-1, IL-2, MMP-1, -3, and TIMP-3 mRNA levels were elevated in both blood 
and myocardium of dogs with cardiac diseases, and also in the myocardium of dogs 
with systemic disease. This might indicate a generalised increased transcription of 
these markers in diseases with cardiac remodelling. 
Dogs with DCM showed a further increase in myocardial MMP-2, TIMP-1 and 
TIMP-2 transcription, when compared with dogs suffering from other cardiac 
diseases. This was also reflected by the more severe cardiac histological changes in 
the heart. However, as these dogs were also in the most advanced disease stages 
(heart failure class D, in contrast to class B and C3 of dogs with other cardiac 
diseases), association of marker expression and of histological changes with the 
severity of the disease instead of the actual disease type appears likely.  
Previous investigations found increased myocardial IL-6 transcription (Oyama 
and Chittur, 2006) as well as increased valvular TGF-β1, TGF-β3, MMP-1, MMP-3, 
TIMP-1, -2 and -3, reduced MMP-2 and variable MMP-9 production in dogs with 
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DVD (Oyama and Chittur, 2006; Aupperle et al., 2008; Aupperle et al., 2009b; 
Ljungvall et al., 2011; Obayashi et al., 2011). The levels of circulating IL-2, IL-7 and 
IL-8 protein were reduced in dogs with DVD (Zois et al., 2012). In contrast to these 
results, studies I and III revealed elevated circulating IL-2 and myocardial MMP-2 
mRNA levels in dogs with cardiac diseases. These differences in results are 
consistent with different material (valves versus myocardium) and diseases 
investigated, and the measurement of protein versus mRNA. The expression of 
TIMP-1 and TIMP-2 was increased in valvular tissue of dogs with DVD (Oyama and 
Chittur, 2006; Aupperle et al., 2009b) and in myocardial samples of dogs with DCM 
(Study III), which suggests that fibrosis might be an important component in both 
diseases. 
Interestingly, not only pro-inflammatory markers, but also the anti-inflammatory 
cytokine IL-10 and the immune modulator IFN-γ were elevated in dogs with cardiac 
diseases (Study II). This suggests limitation of the inflammatory reaction by IL-10, 
since it inhibits the production of pro-inflammatory cytokines (Fiorentino et al., 1991; 
Mosmann, 1994; Krishnamurthy et al., 2009). IL-10 is also known as a Treg cell 
product, and Treg cells are anti-inflammatory which reduces fibrogenesis (Kvakan et 
al., 2009; Tang et al., 2012). IFN-γ is associated with a Th1 cell polarisation, and Th1 
cells are also suspected to limit fibrosis (Mosmann et al., 1986; Zhu et al., 2010; Wei, 
2011). Accordingly, IL-10 and IFN-γ might have a cardioprotective function. 
However, in the end-stage of cardiac diseases, the marked inflammatory reaction 
might override these regulatory components, which would indicate that the increase 
in IL-6, TNF-α and IL-10 observed in dogs in study II predicts a poor outcome, as 
reported in people with decompensated heart failure (Miettinen et al., 2008). On the 
other hand, the anti-fibrotic effects of IL-10 and IFN-γ might also reflect progressive 
cardiac remodelling. 
In studies II and III, the expression levels in the different cardiac regions were 
compared. In dogs with cardiac and systemic diseases, atria generally showed 
higher transcription levels than ventricles. These differences matched with the 
observed extent of pathological changes identified by the histological examination in 
dogs with cardiac diseases (leukocyte infiltration, lipomatosis cordis, cardiac fibrosis, 
muscular hypertrophy of small arteries, cardiomyocyte necrosis) and confirm 
previous reports that suggested differences in the remodelling processes in atria and 
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ventricles (Hanna et al., 2004; Brundel et al., 2005). Furthermore, dogs with cardiac 
disease showed significantly higher atrial IL-1, IL-8, TNF-α, TGF-β1 and TGF-β3, 
and dogs with atrial fibrillation higher MMP-2, MMP-13 and lox transcription, than 
dogs with systemic diseases (Studies II and III). This increase in inflammatory and 
pro-fibrotic marker expression in the atria of dogs with cardiac diseases might 
contribute to atrial dilatation, atrial arrhythmia, cardiac dysfunction and therefore 
progression of disease (Khan et al., 2004; Khan and Sheppard, 2006; Mukherjee et 
al., 2006). In dogs with atrial fibrillation (which had been diagnosed in three dogs 
with DCM and one with DVD in the present study), MMP-2 and MMP-13 might cause 
ECM degradation which could allow the observed left atrial dilatation, and lox might 
cause increased collagen crosslinking (Mukherjee et al., 2006; Lopez et al., 2010), 
both factors known to contribute to the development of atrial fibrillation (Mukherjee et 
al., 2006; Adam et al., 2011).  
6.2 Markers of inflammation and ECM remodelling in dogs 
with systemic diseases 
It has been shown in people and dogs that systemic diseases can lead to 
myocardial dysfunction and damage (Parker et al., 1984; Nelson and Thompson, 
2006; Serra et al., 2010; Langhorn et al., 2013). To investigate, whether systemic 
diseases induce cardiac inflammation and remodelling, dogs with systemic diseases 
not involving the heart were included in studies II and III. The histological 
examination did not reveal any remarkable pathological changes in the heart of 
these dogs. Nonetheless, the transcription of all markers for inflammation and ECM 
remodelling was significantly elevated in comparison to controls. In particular the 
increase of inflammatory markers might be due to generalised activation of the 
inflammatory system in the course of the dogs’ neoplastic and systemic diseases 
(Seruga et al., 2008; Flynn et al., 2010; Langhorn et al., 2013). Unfortunately, this 
could not be further investigated, since circulatory transcription levels were not 
measured in these dogs. Inflammatory cytokines affect cardiac function, facilitate 
cardiomyocyte hypertrophy and apoptosis and are involved in remodelling processes 
by stimulating MMP and TIMP production (Bradham et al., 2002b; Siwik and Colucci, 
2004; Chen et al., 2008; von Haehling et al., 2009). The latter are major 
determinants of pathological ECM remodelling and contribute further to an 
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inflammatory response (Spinale, 2007; Sivakumar et al., 2008). Therefore, the 
combination of an increased myocardial cytokine expression with dysregulation of 
MMP and TIMP expression could affect ECM composition and cardiac function and 
thereby morbidity and mortality in these patients (Studies II and III). However, the 
absence of histological changes in the heart that would indicate ongoing 
inflammatory and/or remodelling processes suggest that the marker upregulation 
might be a component of the end-stage disease only, leading to acute functional 
changes that had been absent earlier (Nelson and Thompson, 2006). Since detailed 
morphological or functional myocardial investigations, such as echocardiography, 
had not been performed on these patients, it is not possible to further comment on 
the latter as part of the present study. However, the apparent inflammatory state of 
the myocardium of dogs with diseases not affecting the heart is of interest and 
suggests that functional changes and generalised cardiac remodelling processes 
occur in end-stage systemic diseases. It needs further investigations to determine 
whether these are indeed acute and reversible or whether they might contribute to 
morbidity and mortality in these cases.  
6.3 Constitutive transcription of markers of inflammation 
and ECM remodelling in healthy control dogs 
To identify the constitutive expression of inflammatory and ECM remodelling 
markers, studies I, II and III included control dogs. Blood samples of healthy control 
dogs in study I showed constitutive mRNA expression of several pro-inflammatory 
(IL-1, IL-2, IL-6, IL-8, TNF-α, IFN-γ) and anti-inflammatory cytokines (IL-10, TGF-β1, 
TGF-β3), and of both anti-fibrotic (MMP-1, -3, -9) and pro-fibrotic markers (TIMP-1, -
2, and -3), albeit at generally lower levels than in diseased dogs in the same study. 
This finding indicates that circulating leukocytes are generally slightly activated; on 
the other hand, it does not mean that the proteins are indeed translated or even 
released into the blood. In contrast, in the myocardium of the healthy control dogs, 
only TNF-α, TGF-β1, TGF-β3, TIMP-3 and TIMP-4 were transcribed (Studies II and 
III), suggesting that cells in the myocardium only express a set of markers that 
maintain the structural balance in the heart and need an (external) stimulus to 
change their transcription pattern. Baseline expression of TGF-β1, TGF-β2, TGF-β3, 
MMP-2, MMP-9 and TIMP-3 mRNA has previously been reported in the heart of 
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dogs (Aupperle et al., 2008; Aupperle et al., 2009b). However, these studies 
focussed on the mitral valve leaflets and did not investigate the expression of 
inflammatory cytokines. Heart valves consist mainly of interstitial cells, 
glycosaminoglycans, proteoglycans, collagen and elastic fibres and are exposed to 
different strains than the myocardium (Fox, 2012; Lacerda et al., 2012), which is the 
likely reason for the observed differences in ECM marker transcription. Nonetheless, 
the transcription of profibrotic markers TGF-β1, TGF-β3 and TIMP-3 in valves and 
myocardium (Study 3) suggest a balance towards anti-inflammation and 
regeneration and/or fibrosis in the healthy canine heart (Aupperle et al., 2008; 
Aupperle et al., 2009b). 
Interestingly, there is an apparent sex difference in the level of constitutive 
myocardial marker transcription, which was not observed in the blood (Study I, data 
not shown) of control dogs. The myocardial transcription levels of TNF-α, TGF-β1, 
TGF-β3, TIMP-3 and TIMP-4 were higher in male than in female control dogs 
(Studies II and III). However, in male dogs with cardiac and systemic diseases the 
myocardial transcription of TNF-α, TGF-β1, TGF-β3 was lower than in male control 
dogs, whereas in female dogs with disease an increase of these markers was 
present (Study II). These findings in male control dogs and female dogs with cardiac 
disease suggests either cardioprotection due to their anti-inflammatory effects and 
the stimulation of regulatory T cells (Shah and Qiao, 2008; Kvakan et al., 2009; Li et 
al., 2010), or increased cardiac fibrosis, associated with either higher regenerative 
capacity or progression of disease (Lim and Zhu, 2006; Aupperle et al., 2008). Lower 
levels in female control dogs and male dogs with cardiac disease on the other hand 
might indicate a pro-inflammatory response or lesser fibrosis. Despite reported sex 
differences in clinical signs and progression of canine DCM and DVD (Serfass et al., 
2006; Wess et al., 2010), the potential influence of sex on the development of 
cardiac diseases is usually not taken into account, because most dogs are neutered, 
as they were in the present studies. However, differences between sexes might be 
underestimated in development, presentation and progression of canine cardiac 
diseases. 
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6.4 Leptin in cardiac and systemic diseases 
Similar to several of the inflammatory and ECM remodelling markers, leptin 
transcription was significantly elevated in the blood and myocardium of dogs with 
cardiac diseases and was associated with disease severity (Study IV). It is now 
known that leptin is not only an important hormone in obesity, regulating energy 
homoeostasis, but is also involved in inflammation (Igel et al., 1997; Faggioni et al., 
1998; Loffreda et al., 1998; Fernandez-Riejos et al., 2010). The results of study IV 
showed that leptin is produced by the myocardium with higher transcription in dogs 
with cardiac diseases, and in particular in atria of these diseased dogs. These results 
are in accordance with those reported from human patients with cardiac disease, 
where leptin blood concentrations were found to correlate with the degree of heart 
failure (Schulze and Kratzsch, 2005). The elevated leptin mRNA levels in both blood 
and myocardium of dogs with cardiac diseases suggest a generalised increased 
transcription of leptin. 
The increased leptin transcription in cardiac diseases observed in study IV and 
the simultaneous elevation of inflammatory and ECM remodelling markers (Studies II 
and III), suggest an involvement of leptin in cardiac inflammation and remodelling, 
thereby further supporting findings in human patients with cardiac diseases 
(Filippatos et al., 2000; Schulze and Kratzsch, 2005; Sharma and McNeill, 2005; 
Karmazyn et al., 2007; Schram et al., 2010). The simultaneous increase of these 
markers might also be the consequence of a higher catabolic state and the 
development of cardiac cachexia, which is observed in human and canine cardiac 
patients (Toth et al., 1997; Schulze et al., 2003). However, this possible correlation 
was not investigated further in study IV. The higher myocardial leptin transcription in 
female dogs with cardiac diseases might be due to the generally higher fat content of 
female dogs (German et al., 2010). Increased leptin transcription might contribute to 
cardiomyocyte hypertrophy and increased collagen deposition (Rajapurohitam et al., 
2003; Karmazyn et al., 2007; Schram et al., 2010), which is supported by the 
increased transcription of profibrotic and anti-inflammatory markers TGF-β1 and 
TGF-β3 that were detected in female, but not in male dogs with cardiac diseases 
(Study II). Leptin might therefore play an important role in development and 
progression of canine cardiac diseases, as recently suggested (Mehlman et al., 
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2013), and might contribute to sex differences in progression and clinical 
presentation.  
6.5 Limitations of the studies  
The studies included in the thesis are limited by the small number of animals that 
were investigated and the inhomogeneity of the groups. The main reason for the 
latter is the very limited access to myocardial samples, therefore, no available dog 
with cardiac disease was excluded from the study and only dogs with end-stage 
diseases could be included. Larger sample sizes and the collection of samples from 
specific disease groups would have strengthened the significance of the results and 
would have enabled the comparison of different diseases. Furthermore, since the 
examination was restricted to the assessment of mRNA expression, comments on 
translation and release of the respective proteins cannot be made. A direct 
conclusion can also not be drawn about the presence of active enzymes, in 
particular also since TGF-β and MMP are secreted in a latent form and require 
cleavage before they become activated.  
6.6 Implications for further studies 
1. The analysis of IL-1, IL-2, MMP-1, -3, and TIMP-3 mRNA and protein (these were 
increased in the blood and myocardium of diseased dogs) in blood samples of 
dogs in different stages of cardiac diseases and its correlation with 
echocardiographic investigations that assess myocardial morphology and 
function would detect changes in progression of disease and identify potential 
biomarkers for cardiac remodelling.  
2. Further characterisation of myocardial remodelling by investigating the protein 
expression of inflammatory and ECM remodelling markers, the presence of 
fibrosis, myocardial degeneration and apoptosis, activation of endothelial cells, 
infiltration of inflammatory cells and the presence of cardiac stem cells would 
reveal further details of the pathogenesis of cardiac diseases. 
3. Increasing the sample size of one cardiac disease, i.e. DCM, and the correlation 
of clinical findings and echocardiographic results with parameters of cardiac 
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inflammation and remodelling would strengthen the significance of the results and 
possibly identify clinical parameters of cardiac inflammation and remodelling.  
4. The correlation of echocardiographic results with the expression of inflammatory 
and ECM remodelling markers in the blood and, if available, the myocardium of 
dogs with systemic diseases and the association of these results with survival of 
these dogs would allow further assessment of the importance and the time 
course of cardiac impairment and remodelling in dogs with systemic diseases.  
5. Further investigation of the role of leptin in cardiac cachexia and in obese dogs 
and its association with cardiac function are of interest and would reveal the real 
significance of leptin in canine cardiac diseases. Furthermore, the investigation of 
other adipocytokines, such as adiponectin, resistin, visfatin, which were reported 
to be involved in human cardiac diseases, would give information on their role in 
canine cardiac diseases. 
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7 CONCLUSIONS 
I Studies investigating the role of inflammation and ECM remodelling in dogs with 
cardiac and systemic diseases in comparison to healthy controls (Studies I, II and III) 
led to the following conclusions. 
1. The significantly higher expression of all markers of inflammation and ECM 
remodelling in the myocardium of dogs with cardiac diseases in comparison to 
hearts of healthy control dogs, whilst only single markers were elevated in the 
blood of dogs with cardiac diseases, suggest primary myocardial inflammation 
and ECM remodelling in dogs with cardiac diseases and not a myocardial 
response to circulating inflammatory mediators.  
2. The higher transcription levels of most markers of inflammation and ECM 
remodelling in atria than ventricles of dogs cardiac and systemic diseases, which 
matched with the observed extent of pathological changes in dogs with cardiac 
diseases, suggest different remodelling processes depending on localisation. 
These differences in inflammation and ECM remodelling are likely to contribute to 
progression of disease, cardiac dysfunction and development of arrhythmias. 
3. The increased expression of inflammatory and ECM remodelling markers in the 
myocardium of dogs with systemic diseases not involving the heart, in the 
absence of histological changes in the heart, might indicate acute functional 
changes in end-stage diseases. The apparent inflammatory state of the 
myocardium of dogs with systemic diseases might be acute and reversible or 
might contribute to morbidity and mortality of these dogs. 
4. The constitutive expression of profibrotic markers in the myocardium of healthy 
control dogs suggests a regenerative and profibrotic potential of the healthy 
canine myocardium.  
II The increased transcription of leptin in the blood and myocardium of dogs with 
cardiac diseases (Study IV) and the simultaneous elevation of inflammatory and 
ECM remodelling markers (Studies II and III) suggest an involvement of leptin in 
cardiac inflammation and remodelling in dogs with cardiac diseases.   
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